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CHAPTER 1: INTRODUCTION 
Portions of the text and figures in this chapter were reprinted or adapted from DNA repair 
journal, Vol 27, Wei, S., Shalhout, S., Ahn, Y., Bhagwat, A.S., A versatile new tool to quantify 
abasic sites in DNA and inhibit base excision repair, Pages 9-18, Copyright (2015), with 
permission from Elsevier.  
1.1 Abasic (AP) sites in cellular DNA 
Deoxyribonucleic acid (DNA) is a biopolymer that carries unique genetic information of 
an organism. Maintaining the integrity and stability of DNA is essential to the survival, function, 
and reproduction of an organism. However, DNA integrity is always challenged by endogenous 
or exogenous agents resulting in DNA damages. If unrepaired, DNA damage could cause 
mutations and a variety of diseases. Therefore, to preserve genome stability, cells have evolved 
to correct damages in DNA through several repair systems such as direct repair (DR), nucleotide 
excision repair (NER), mismatch repair (MMR), base excision repair (BER), homologous 
recombination (HR), and non-homologous end joining (NHEJ) [1]. 
DNA damages are defined as alterations to the chemical structure, which could be 
strand breaks, base modifications, bulky adducts, crosslinks or base loss. For example, 
ionization radiation can induce single and double-strand breaks in DNA [2]. Reactive oxygen 
species generated during normal metabolic processes in cells can oxidize guanines into 8-
oxoguanines [3]. Bulky adducts in DNA are created by the exposure to carcinogens such as 
polycyclic aromatic hydrocarbons (PHAs) [4].  Some chemotherapeutic agents like 1, 3-bis(2-
chloroethyl)-1-nitrosourea (BCNU) can give to DNA crosslink by methylating guanines [5]. Base 
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loss arises from several different ways and leads to the formation of abasic (AP) sites [6], which 
are particular interest to our lab. 
 Many DNA-damaging chemotherapeutic drugs can induce the formation of AP sites [7]. 
Thus detection and quantification of AP sites will provide a useful tool for monitoring the effect 
of drug during the development of chemotherapies. Furthermore, AP sites are created and 
repaired through BER pathway. Recently, inhibition of BER has been a potential strategy to 
overcome therapeutic drug resistance and enhance the potency of chemotherapies. As AP sites 
are involved in this repair pathway, blocking BER by targeting AP sites will provide a novel 
strategy for cancer therapy [8]. The work presented explores the detection of AP sites in 
cancers as well as targeting AP sites to improve anti-tumor chemotherapy.  
1.1.1 Formation of abasic sites 
An AP (apurinic/apyrimidinic) site is considered to be the most commonly generated 
lesion in DNA, which is derived from a loss of base through the hydrolytic cleavage of N-
glycosidic bonds, leaving a deoxyribose residue in DNA (Figure 1). Numerous endogenous 
/exogenous agents as well as innate cellular processes can create AP sites in DNA. AP sites are 
formed in cellular DNA through spontaneously water-mediated depurination and 
deprimidination[9]. About 10,000 AP sites are generated in this way in a human cell every 
day[10]. The process of depurination is pH and temperature dependent, and either heat or 
acidic condition greatly accelerates the rate of depurination. Hence, heat/acid treatment is a 
common method used for induction of AP sites in DNA[11]. At 70°C and pH 7.4 condition, the 
rate of depurination of native DNA is 4x10-9 sec-1. However, hydrolytic depurination also 
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spontaneously occurs at a significant rate under physiologic conditions (ƙ=3x10-11 sec-1) [9]. 
Hydrolytic depyrimidination happens at a lower rate compared to depurination [12]. 
 
Figure 1 Formation of abasic (AP) sites in DNA through depurination. 
 
AP sites are also created through the action of agents that react with DNA. For example, 
DNA alkylating agents such as temozolomide (TMZ) transfer an alkyl group to guanine base at 7 
nitrogen position. The alkylation of 7-nitrogen of guanine destabilizes the glycosidic linkage by 
giving a positive charge on the guanine ring and converts guanine into a good leaving group, 
and increases the rate of depurination. A number of other alkylated bases including N3-
methylguanine, N3-methyladenine and N7-methyladenine similarly facilitate the loss of purine 
residues [12]. 
Furthermore, many damaged bases are repaired via the BER pathway, which starts with 
the excision of the damaged base by a DNA glycosylase forming an AP site. Subsequently, AP 
endonuclease (APE) incises the DNA backbone at the AP site and creates a single-strand break 
resulting 5'-deoxyribose-phosphate (5’dRP) end, which is further removed by polymerase β (Pol 
β). Finally, the correct nucleotide is incorporated by Pol β, and the remaining nick is sealed by 
DNA ligase [13] (Figure3). This BER pathway is called ‘short-patch repair’. BER pathway can also 
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take place by ‘long-patch repair’, in which more than one nucleotide are inserted by 
polymerases. In long-patch BER, proliferating cell nuclear antigen (PCNA), flap structure-specific 
endonuclease 1 (FEN1) and DNA ligase are required to work together and remove the 
generated flap and seal the nick. Short-patch BER is the dominant pathway. However, when AP 
sites are reduced or oxidized or when the 5’-dRP intermediate generated by AP endonuclease is 
refractory to the removal action of pol β, the long-patch BER proceeds to repair DNA [14]. 
Damaged DNA bases arising from alkylation, oxidation and deamination of normal bases are 
primarily repaired by BER pathway, producing AP sites as intermediates. Although the 
glycosylase action is normally coupled with other BER enzymes that process the AP sites, an 
imbalance in the repair enzymes may cause the AP sites to persist. 
 
Figure 2.Creation and repair of AP sites in base excision repair pathway. AP sites are created 
through the action of DNA glycosylase. Subsequently, AP endonuclease (APE) cleaves DNA 
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backbone at AP sites to create a single-strand break. The nick can be processed in either short-
patch pathway or long-path pathway. In short-patch BER, polymerase β (Pol β) removes 
remaining 5'-deoxyribose-phosphate (5’dRP) and incorporates the correct complementary 
deoxynucleotide, and finally the nick is sealed by DNA ligase III. In long-patch BER, polymerases 
ẟ/ɛ insert at least two nucleotides at the single-strand break generated by APE, and FEN1 is 
responsible for removing the flap. DNA ligase I seals the gap and accomplishes DNA repair. This 
figure was modified from figures in the references [13-15].  
 
1.1.2 Repair and biological consequence of AP sites 
BER is the principal pathway responsible for repairing AP sites lesions in DNA. However, 
other DNA repair pathway may also be able to remove AP sites. Nucleotide excision repair is 
known to repair bulky lesions[16]. But, there are some evidences showing that NER pathway 
acts as a backup for removing AP sites in E. coil cells and yeast, when BER does not function 
very well [17, 18]. If unrepaired, AP sites potentially cause cell death or mutagenesis by 
blocking DNA replication and transcription. Replicative DNA polymerases cannot copy AP sites, 
and the progress of the replication fork is blocked at AP sites causing single-and double-strand 
breaks. Alternatively, AP sites may be copied by error-prone translesion-synthesis (TLS) 
polymerases that cause base substitution mutations, but allow replication to continue [19]. The 
strand breaks resulting from unrepaired AP sites may be repaired using error-free HR, or may 
be repaired by a NHEJ process that creates small addition/deletion mutations. If unrepaired, 
the strand breaks lead to gross chromosome alterations such as translocations and cause cell 
death [17]. Thus the creation of AP sites in the genome and their processing by cellular 
machinery has profound implications for genome integrity. 
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Figure 3 Biological consequences of AP sites. AP sites are primarily repaired by BER pathway, 
and they can be removed by nucleotide excision repair (NER) pathway when base excision 
repair (BER) is defective. Also, AP sites can be tolerated by translesion synthesis which induces 
mutations. If unrepaired, AP sites could block DNA replication fork inducing DNA breaks. The 
resulting breaks might be processed through homologous recombination (HR) or non-
homologous end-joining (NHEJ); otherwise, these breaks would lead to cell death.  
 
1.1.3 Chemistry of AP sites 
NMR spectroscopy analysis of AP site in synthetic oligodeoxynucleotides suggested that 
AP sites might exist in equilibrium between three chemical forms: cyclic hemiacetals, open-
chain aldehydes and hydrated aldehydes (Figure 4A). A mixture of α and β cyclic hemiacetal 
forms (around 1:1 ratio) are predominant, while the aldehyde form only makes up 1~5 % [20]. 
However, the open-chain aldehydes are most reactive. Aldehydes in the open form of AP sites 
ligate to alkoxyamines forming stable oximes. Taking the advantage of the reactivity of AP sites 
with alkoxyamine compounds, many techniques have been developed for the study of AP sites. 
For example, aldehyde-reactive probe (ARP) and methoxyamine (MX) are two well-known 
alkoxyamines widely used for labeling AP sites (Figure 4B). Furthermore, AP sites are sensitive 
to alkaline conditions due to the presence of the aldehyde form. In mild alkaline condition, AP 
sites undergo a β-elimination reaction yielding α, β-unsaturated sugar residue. A stronger 
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alkaline condition can induce a second elimination called δ elimination, and the, β-unsaturated 
aldehyde is further degraded [21]. Also, under neutral heat condition, AP sites are shown to be 
thermally degraded through β-elimination reaction [22] (Figure 4C). 
 
 
 
Figure 4 Chemistry of AP sites. (A) Structural forms of an AP site. (B) The reaction between AP 
sites and alkoxyamines such as methoxyamine and ARP. (C) The reactivity of AP sites under 
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alkaline and heat condition. The mild alkaline or heat condition promotes a β-elimination 
reaction resulting in the formation of α, β-unsaturated sugar. Under the strong alkaline 
condition, AP sites can be further degraded through a δ elimination reaction.  
 
1.1.4  Detection and quantification of AP sites in DNA 
Utilizing the reactivity of AP sites, many assays for quantification of these DNA lesions 
have been developed. Most of the techniques are based on the reaction of an aldehyde residue 
of AP sites with alkoxyamines as previously mentioned. Radioisotope-labeled methoxyamine 
(14C-methoxyamine or 11C-methoxyamine) has been used to determine AP sites in DNA treated 
with peroxynitrite [23] or visualize AP sites in vivo [24]. The number of AP sites are proportional 
to the radioactivity of methoxyamine in DNA. This quantitative assay shows high sensitivity with 
a limit of detection of 1 AP site per 1millon nucleotides [23]. With the fast development of 
chromatographic separation and mass spectrometry technologies, high-performance liquid 
chromatography (HPLC) and tandem mass spectrometry (MS/MS) techniques provide a more 
accurate method to measure AP sites. DNA containing AP sites are labeled with an alkoxyamine 
called O-4-nitrobenzylhydroxylamine (NBHA), followed by digestion with a deoxyribonuclease 
(DNase) into mononucleotides. NBHA-tagged monomeric subunits are isolated and detected by 
HPLC-MS/MS. This method shows not only high sensitivity with a limit of detection of 3 AP sites 
per 107 nucleotides but also can discriminate intact AP sites from cleaved AP sites such as 5’-
deoxyribose monophosphate (5’-dRP) [25]. However, it is very difficult to use these techniques 
with a large number of samples because they either use equipment such as HPLC and MS/MS or 
use radioisotopes that are incompatible with a clinical setting. In addition, these methods 
require a large amount of DNA. Another simple quantitative assay for AP sites involves in 
fluorescently labeled alkoxyamines which allow linking fluorescent tagged to AP sites for 
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detection, but this method shows low sensitivity with a limit detection of 1 AP site per 1x105 
nucleotides [26].  
Consequently, the most commonly used method for the detection and quantification of 
AP sites is based on the reaction of ARP which reacts with the open form of aldehyde residue in 
AP sites. An advantage of the use of ARP in labeling AP sites is that multiple samples can be 
processed in parallel, and the reaction products can be spotted on a membrane to create an 
ELISA-like assay. ARP has been used to determine AP sites in different mammalian tissues [27], 
to monitor changes in AP sites during aging [28] and AP sites generated as a result of treatment 
of cells with carcinogens [29]. It has also been adapted to quantify genomic uracils by excising 
uracils by uracil-DNA glycosylase to create AP sites followed by ARP treatment [30, 31]. It has 
been used to determine uracil levels in normal and repair-deficient Escherichia coli cells [31], in 
normal mammalian tissue and cancer cells [32]. However, ARP-based assays for AP sites suffer 
from several drawbacks. ARP contains biotin which is also present in a cell and hence 
fluorescent labeling of AP sites in living or fixed tissues using ARP results in a considerable 
background. ARP is bulky (MW 331.4), and its reaction with AP sites is likely to be significantly 
hindered. The presence of biotin within ARP also necessitates the use of protein like 
streptavidin making the labeling scheme cumbersome and somewhat expensive. Finally, a 
detailed study of ARP reactivity with AP sites has shown that the reaction creates side products 
in addition to ARP linked to full-length DNA [33]. 
1.2 The role of abasic sites in cancer chemotherapy 
DNA-damaging agents are a major type of chemotherapeutic drugs for cancer treatment. 
These agents target DNA in cells and introduce a variety of DNA damages including DNA breaks, 
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base modifications and strand crosslinks. Most cancer cells often display specific abnormalities 
in DNA damage response and DNA repair pathways [34]. Due to this property of cancers, DNA-
damaging agents have been widely developed to kill cancer [35]. However, the use of many 
DNA-damaging drugs is primarily limited by the development of drug resistance. In many cases 
of failure of treatment with DNA-damaging agents, the resistance arises from a change in repair 
proteins expression and increased DNA repair capacity [36-38]. To strengthen DNA-damaging 
agents and overcome drug resistance, disruption of DNA repair pathway is a rational approach 
[34, 39].  As BER is the major pathway responsible for repairing most DNA lesions introduced by 
DNA-damaging agents [40-42], a number of small-molecule inhibitors of BER proteins such as 
APE1, PARP-1, and Pol β have been used in combination chemotherapy with DNA-damaging 
agents [39]. AP sites as the crucial intermediates in BER pathway could also be the target of 
anticancer drugs. A small alkoxyamine, MX, works as a BER inhibitor by chemically modifying AP 
sites induced by DNA-damaging agents and has been proposed as an anticancer agent in 
combination with alkylating agents such as temozolomide [43]. Thus, blocking the repair of AP 
sites could be a promising approach to eliminating drug resistance and improve the 
chemotherapeutic outcome of DNA-damaging agents. 
1.2.1 DNA-damaging agents in chemotherapies 
Chemotherapeutics agents have been used in cancer treatment for decades and are still 
the most prevalent treatment, since the first drug, nitrogen mustard was used for curing 
lymphoma and leukemia tumors during world War II [44]. In the 1960s, the mechanism of killing 
cancer cells by nitrogen mustard was elucidated. The ability of nitrogen mustard to kill tumors 
is based on its property of DNA damaging. When cells have the high level of DNA damage, DNA 
11 
 
 
damage response and repair pathways are activated to maintain genome integrity and prevent 
transferring damaged DNA to daughter cells. If damaged DNA was not repaired prior to S phase 
in cell proliferation, the progress of DNA replication would be blocked by damaged bases. This 
would subsequently lead to accumulation of deleterious DNA double-strand breaks (DSBs). 
DSBs are principally repaired by either NHEJ or HR pathway. If left unrepaired, cells will be 
arrested or undergo apoptosis [35] (Figure 5). In normal cells, cell-cycle checkpoints are 
responsible for sensing DNA defects then activating DNA damage response and repair pathways 
to induce either cell cycle arrest, DNA repair, or cell apoptosis. However, human cancer cells 
often ignore cell cycle checkpoints, continuing DNA replication in the presence of damaged 
DNA [34]. This increases the likelihood of formation of DSBs and cell death during DNA 
replication when cancer cells are exposed to DNA-damaging agents. Therefore, this confers 
cancer cells higher susceptibility to DNA damages. Moreover, human tumors typically show 
aberrations in DNA damage response or repair. Inactivation of DNA damage response was 
observed in various cancers, due to mutation and deletion of P53 gene or decreased expression 
of ataxia telangiectasia mutated (ATM)), BRCA1, and MRN complex [35, 45, 46]. However, in 
some cases, proteins involved in ATM-mediated DNA damage response are upregulated, and 
this induces resistance of cancer cells to DNA-damaging agents. Also, many cancers have 
deficiencies in a certain DNA repair pathway and may be more susceptible to a specific type of 
DNA damage [35].  
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Figure 5 Overview of DNA damage and response pathways. DNA-damaging agents introduce 
DNA damages including base modifications, crosslinks and single-strand breaks (SSBs). Each 
type of lesions is processed by a specific repair pathway such as base excision repair (BER), 
nucleotide excision repair (NER), mismatch repair (MMR) and direct repair (DR). Unrepaired 
damaged DNA could stall DNA replication fork and induce double-strand breaks (DSBs). In 
response to DSBs, DNA damage responses are activated to promote cell cycle arrest, cell 
apoptosis or DSB repair by homologous recombination (HR) /non-homologous end joining 
(NHEJ)/alternative NHEJ (alt-NHEJ). The figure was modified from a figure in the reference [35]. 
 
A large number of antitumor drugs targeting DNA have been developed and clinically 
used in the treatment of cancers. Based on the mechanism of action, DNA-damaging agents can 
be classified into three categories including DNA-reactive agents, antimetabolites and 
topoisomerase poisons (Table 1). DNA-reactive agents represent a class of antitumor 
compounds that directly react with DNA leading to modified bases or cross-linking of DNA. For 
example, DNA alkylating agents include the nitrosoureas family of compounds (nimustine, 
carmustine and lomustine) and triazene compounds (dacarbazine, procarbazine and 
temozolomide) [47].  These drugs directly alkylate DNA causing replication fork collapse and 
consequently killing cancer cells. Another example of DNA reactive agents is cisplatin, a 
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platinum-containing drug, which forms an adduct in DNA inducing the formation of intrastrand 
crosslinks [48]. Cisplatin has been successfully used to treat various types of cancers such as 
testicular, bladder, cervical, ovarian, lymphomas, etc [49]. Another class of DNA-targeted drugs 
is antimetabolites that mimic normal cellular metabolites interfering with DNA synthesis and 
replication and leading to cell apoptosis. A number of nucleobase analogs such as 5-fluorouracil 
(5-FU) are widely used as antimetabolite anticancer drugs.  The cytotoxicity of 5-FU results from 
its misincorporation in DNA as well as inhibition of thymidylate synthase [50]. In addition, other 
antimetabolites such as pemetrexed, methotrexate and aminopterin can inhibit enzymes 
involved in DNA synthesis to prevent cancer cell growth [51, 52]. The third class of DNA-
damaging agents is topoisomerase poisons. Topoisomerases including topoisomerase I and II 
are enzymes responsible for overwinding or unwinding the supercoiled structure of DNA, and 
they are essential for DNA replication and transcription. Etoposide, an inhibitor of 
topoisomerase II, works as a cytotoxic antitumor drug by targeting DNA-topoisomerase 
complex, inhibiting religation of strand breaks and resulting DSBs [53, 54]. 
Table 1 DNA-damaging agents used in the chemotherapy. 
Category DNA-damaging agents Actions 
 
 
DNA-reactive agents 
Alkylating agents: Nimustine, Carmustine ,   
Lomustine, Dacarbazine, Procarbazine and 
Temozolomide.  
Alkylation of bases 
Crosslinks 
 
Platinum-based agents: Cisplatin, Carboplatin, 
and Picoplatin 
Crosslinks 
Antimetabolites 5-Fluorouracil, Pemetrexed and Methotrexate Inhibition DNA 
synthesis 
Topoisomerase 
poisons 
Etoposide, Doxorubicin, Daunorubicin, Camptothecin 
and Mitoxantrone 
Topoisomerase 
poison 
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One major limitation of the use of DNA-damaging agents in cancer chemotherapy is 
drug resistance. The development of resistance is the primary cause of failure of 
chemotherapies. Tumors acquire resistance to drugs in a number of ways. In some cases, drug 
resistance results from decreasing drug uptake or increasing drug efflux. In many cases, tumors 
become resistant to DNA damaging agents by overexpressing proteins in DNA repair pathways 
and increasing tolerance to DNA damage. Therefore, targeting DNA repair pathway is a 
potential and rational strategy to overcome resistance and enhance antitumor efficacy of DNA-
damaging agents. 
1.2.2 BER inhibitors in combination chemotherapy 
Most cancer cells have defects in either DNA or DNA repair pathway [55]. DNA damage 
is mostly processed through multiple repair pathways. In cancer cells, deficiency in one repair 
pathway is compensated by an alternative pathway. Disrupting DNA repair may block backup 
repair in cancer cells and lead to cell death [56]. But normal cells will be intact because they 
have proficient compensatory repair system (Figure 6). Therefore, interrupting DNA repair 
pathway is a promising strategy to kill cancer.  The purpose of use of DNA-damaging agents in 
cancer chemotherapy is to increase the level of DNA lesions and overload DNA repair capacity. 
The majority of damaged DNA induced by DNA-damaging agents is repaired through base 
excision repair pathway, which is essential for both normal and cancer cells.  
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Figure 6 DNA repair in normal and cancer cells. Normal cells process DNA damage by multiple 
pathways (A and B), while cancer cells defective in pathway A repair DNA by compensatory 
pathway B. When the pathway B is inhibited, both pathways are defective in cancer cells. This 
would cause cell death. However, normal cells can survive because the pathway A can 
compensate the inhibition of pathway B. The figure was modified from figures in the references 
[35, 57]. 
 
Tumor’s sensitivity to DNA-damaging agents is affected by BER imbalances as a 
consequence of alterations in the activity or expression level of BER enzymes. Mice deficient in 
alkyladenine-DNA glycosylase (AAG) and mice with overexpressed AAG have been used to study 
the consequence of an imbalance of BER initiation step [58, 59]. AAG excises damaged bases 
formed by alkylating agents and initiates BER, resulting in the accumulation of toxic 
intermediates AP sites. Overexpression of AAG has been reported to sensitize mice to MMS 
treatment. And Aag-/- mice showed remarkable resistance in response to alkylating agents, 
compared to wild-type mice [60].  However, inhibition of BER initiation does not always exhibit 
protection against all alkylating agents [61, 62].  In addition, imbalance of downstream BER can 
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also alter the sensitivity of cells to DNA-damaging agents. Kelley group found the elevated 
expression of APE1 in human osteosarcoma samples conferred resistance to antitumor 
treatments including DNA alkylating agent chemotherapy and ionizing radiation, while 
osteosarcoma cell lines treated with APE1-siRNA exhibited sensitivity to DNA-damaging agents 
due to decreased level of APE1 proteins [63]. Moreover, it was reported that cells defective in 
polymerase β showed increased sensitivity to DNA alkylating agents [64]. Altogether, these 
results indicate that imbalance of BER is essential for the sensitivity and resistance to 
therapeutic damaging agents. Therefore, blocking BER downstream pathways provides a 
potential approach to enhance the cytotoxic effect of DNA-damaging agents in cancer 
treatment and conquer drug resistance. There has been growing interest in the development of 
small molecules inhibitors targeting BER pathway. Many BER inhibitors are in development or 
on the market.  
APE1 is the major AP endonuclease in human, which incises DNA backbone at an AP site 
generated by DNA glycosylase and produces a single-strand break that is further processed by 
downstream enzymes. Many small molecules have been identified to inhibit APE1 activity. 
Some of them have shown the ability to increase cell killing by DNA alkylating agents in 
melanoma and glioma cancer cells [65]. However, they are still in the preclinical stage [52, 63, 
66, 67]. APE1 is a multiple functional enzyme. In addition to DNA repair function, APE1 also has 
the redox function to regulate transcription of genes. E3330 is a specific small inhibitor for APE1 
redox function, which has been used for the treatment of many cancers at the stage of clinical 
trials [40, 68].  However, it does not affect DNA repair function of APE1.  
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Pol β has two functions including lyase and polymerase activities to process the 
remaining breaks with the 5’dRP terminus created by APE1. As the step of removing 5’dRP 
residue by Pol β is rate limiting in BER pathway, Pol β is an attractive candidate for inhibition of 
BER. Moreover, it has been reported that overexpression of Pol β is the cause of resistance to 
irradiation (IR) treatment and DNA-damaging agents therapies in various cancers [35, 69]. A lot 
of natural compounds such as oleanolic acid, edgeworin, harbinatic acid and stigmasterol were 
observed to inhibit the activity of Pol β in biochemical assays [41, 70]. Unfortunately, they 
showed little effect on cytotoxicity of DNA-damaging drugs. Jaiswal group identified two small-
molecule inhibitors of Pol β, NSC666715 and NCS124854, both of which are able to greatly 
enhance the cytotoxic effect of temozolomide in vitro and in vivo at a low concentration [42, 
71]. Additionally, in combination with temozolomide, the two compounds promote killing of 
MMR-deficient cancer cells that are resistant to alkylating treatment [66]. However, additional 
in vivo studies are required before the NCS compounds move to clinical trials.  
DNA ligase is essential for DNA repair and replication. In human, DNA ligase I and III are 
responsible for linking of 3’-hydroxyl and 5’-phosphate terminus at DNA nick to accomplish 
base excision repair. Small molecules were identified to inhibit DNA ligases based on the crystal 
structures [72]. For example, compounds 67 and 189 were observed to enhance drastically the 
cytotoxicity of methyl methanesulfonate (MMS) in breast tumor cells which showed a higher 
level of expression of DNA ligase I than normal tissues [73].  
1.2.3 Methoxyamine as a BER inhibitor in combination therapy 
The inhibitors discussed in section 1.2.2 are targeting enzymes involved in BER pathway. 
Another approach to inhibiting BER pathway is to modify AP sites chemically by a small 
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alkoxyamine, MX, as AP sites are important intermediates in BER pathway. MX has worked as a 
BER inhibitor for many years since Liuzzi et al. first utilized MX as a novel tool to investigate the 
enzymatic reactions in BER pathway in 1985 [74]. The mechanism of disruption of BER by MX 
has been documented. It has been found that MX binds to AP sites faster than APE1 [75]. The 
MX-bound AP site substrate could be not recognized by APE1 or be refractory to the cleavage 
activity of APE1; thereby it protects AP sites against the cleavage of APE1 [8]. However, Wilson 
group reported that MX-bound AP sites could be excised by APE1 with a much lower turnover 
number than intact AP sites. Instead, MX was shown to block the lyase activity of Pol β and 
interrupt Pol β-dependent short-patch BER [76]. They found that MX-bound AP sites can be 
efficiently repaired by long-patch BER rather than NER pathway indicated in previous reports 
[77]. It is still not clear whether MX-AP adducts can be repaired and how cells process these 
adducts.   
MX has been used as a part of combination treatment to enhance the cytotoxic effect of 
DNA-damaging agents in a variety of cancers. It reacts with AP sites induced by DNA-damaging 
agents such as alkylating agents to form MX-AP adducts, which escape repair and stall 
replication fork resulting in cell death (Figure 7). Gerson group first explored the use of MX in 
antitumor treatment. They found that MX increased the therapeutic efficacy of DNA alkylating 
agents, TMZ and BCNU, in colon cancer cell lines as well as human colon tumor mouse 
xenograft [43, 78]. Colon cancer cells with mismatch repair deficiency are resistant to TMZ 
treatment, but MX sensitizes them to TMZ treatment. Moreover, this group showed that MX 
coupling with other DNA-damaging agents is also able to improve their antitumor efficacy. For 
example, MX greatly potentiates the cytotoxicity of pemetrexed in some solid tumors [79]. And 
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the combination of MX with fludarabine improves chemotherapeutic efficacy in chronic 
lymphocytic leukemia [80]. Targeting AP sites by MX as a strategy to enhance antitumor 
efficacy of chemotherapy are also attractive to other investigators. Several groups 
demonstrated that combing MX with TMZ treatment can overcome the resistance of glioma cell 
lines to TMZ treatment [81].  Clinical trial studies of using MX (TRC102) in combination 
chemotherapy are underway or have been completed. The completed phase I clinical trial is to 
evaluate the combination treatment of TRC102 with pemetrexed in lung tumor and other solid 
tumors, and phase 1 studies of TRC102 coupling with TMZ and fludarabine are ongoing.  
 
Figure 7 MX enhances cell killing by DNA damaging agents. DNA damaging agents such as 
temozolomide (TMZ) and pemetrexed introduce DNA lesions, which cause replication fork 
collapse and cell death if they are unrepaired. However, if cancer cells remove lesions by BER 
pathway, cells can survive and display resistance to these agents. MX has the ability to block 
BER pathway by binding to AP sites and inhibiting APE activity. Coupling MX with DNA damaging 
agents overcomes resistance and increases cell death.  
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MX targets not only BER pathway but also inhibits topoisomerases. Topoisomerases are 
essential for the processes of DNA replication, transcription and chromosome segregation. They 
regulate the topology of DNA by cutting one or two strands of a DNA-double helix and then 
reannealing strand breaks.  Based on the number of strand cut in DNA, topoisomerases are 
divided into type I (top I) and II (top II). Interfering with topoisomerases is considered as one 
effective strategy for cancer therapy. Many topoisomerase inhibitors have been developed into 
antitumor therapeutic agents such as etoposide, camptothecin, mitoxantrone and doxorubicin, 
because they increase the level of DNA breaks associated with topoisomerases and lead to 
accumulation of DNA damage and chromosome aberrations [82]. Many evidences have shown 
that AP sites are topoisomerase poisons and are able to induce cell death. When AP sites are 
located at the cleavage site of topoisomerases, the DNA lesions prevent religation of transient 
DNA breaks mediated by topoisomerases, increase enzyme-DNA cleavage complex and convert 
transient double-strand breaks into permanent DNA breaks through DNA replication process 
[83-85]. Under normal conditions, deleterious AP sites can be rapidly repaired through BER and 
do not poison topoisomerases. If AP sites are unrepaired, the persistence of AP sites will result 
in topoisomerase-mediated cytotoxicity (Figure 8). Since MX blocks the repair of AP sites, it 
would indirectly poison topoisomerase. In vitro studies indicated that MX-bound AP sites 
considerably elevated topoisomerase II-mediated cleavage. Furthermore, the combination 
treatment of TMZ and MX increased top II expression as well as DNA double-strand breaks in 
colon cancer cells. And the result of the collocation of top II protein and γ-H2AX suggested that 
the accumulation of DNA breaks is associated with induction of top II expression after TMZ and 
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MX treatment [8, 43]. These findings demonstrate that MX-AP sites are capable to poison 
topoisomerase stimulating topoisomerase-mediated cytotoxicity.  
 
Figure 8 Model for topoisomerase poison by AP site intermediates of BER. Topoisomerase 
inhibitors such as etoposide work as antitumor drugs and kill cells by promoting accumulation 
of DNA breaks mediated by topoisomerase. AP sites arising from the repair of damaged DNA by 
BER can also act as topoisomerase poison, by preventing ligation of topoisomerase-associated 
transient DNA breaks and leading to the permanent existence of DNA breaks. The figure was 
modified from a figure in the reference [83]. 
 
1.3 B-cell lymphomas and abasic sites 
B-cell non-Hodgkin lymphomas (B-NHL) are the sixth most common type of cancers, 
which have various subtypes. The majority of B-NHL originate from germinal centers, in which a 
DNA mutator enzyme, activation-induced deaminase (AID) initiates the processes of somatic 
hypermutation (SHM) and class switch recombination (CSR) for antibody maturation, by 
deaminating cytosines into uracils in immunoglobulin (Ig) loci [86-88]. AID also involves in B cell 
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lymphomagenesis and constitutively expresses in many B-cell lymphomas [89-91].  Recently, 
two papers successively demonstrated that the constitutive expression of AID in B-cell 
lymphomas leads to the accumulation of uracils in their genomes [90, 92] and the high level of 
AID expression positively correlates with an excess of genomic uracils. In BER pathway, uracil-
DNA glycosylases remove uacils forming AP sites. The high level of uracils in B-cell lymphoma 
cells must lead to high level of formation of AP sites intermediates. An imbalance in the 
downstream of BER repair enzymes may cause the AP sites to persist. Therefore, it is highly 
possible that these B-cell lymphoma cells with an excess of uracils would have the high level of 
AP sites intermediates accumulation in their genomes.  
1.3.1 Antibody maturation 
Innate immunity and adaptive immunity constitute the human immune system, which is 
responsible for protecting the body from infection. Innate immunity works as a first defense 
line and eliminates foreign organisms through physical barriers, chemicals and innate immune 
cells.  But it lacks specificity and long-term protection. Adaptive immunity also called acquired 
immunity is mediated by antibodies and cell surface receptors. Unlike innate immunity, the 
adaptive immune system is in response to a specific pathogen and creates memory cells to 
protect the body from infection by the same pathogen for a lifetime.  Also, it recruits antibodies 
made by B lymphocytes to recognize and combat particular foreign objects. Antibodies encoded 
by immunoglobulin gene are glycoproteins with a heterodimer consisting of two heavy chains 
and two light chains. The variable domains are responsible for binding specific antigens, while 
the remaining part composed of constant domains determines antibody isotypes. A human 
without antigen stimulation can produce more than 1012 antibodies allowing binding to 
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different antigens, although the total number of genes in a human genome is fewer than 
50,000 [86]. After stimulation by antigens, the immune system can create antibodies with 
higher affinity to antigens. The question is how the immune system makes a vast number of 
antibodies with a limited number of genes. 
The amazing diversity of antibodies results from the V (D) J recombination, SHM and CSR 
processes. During V (D) J recombination, variable (V), diversity (D) and joining (J) segments in Ig 
genes are rearranged to create a unique combination during early B cell development [93]. 
When B cells are exposed to antigens, further expansion and maturation of antibodies are 
generated through the mechanisms of SHM and CSR. SHM is a process of introducing point 
mutations in V (D) J segment of Ig genes to increase antibody affinity to the particular foreign 
antigen. The rate of SHM is almost 106 fold higher than the normal mutation rate (about 10-9 
per base pair) in the genome, but this mutational process is restricted to V (D) J region [87]. B 
cells with somatic mutations that produce antibodies with better affinity to antigens are 
positively selected for further cell expansion, while mutated B cells secreting antibodies that 
show decreased affinity are eliminated through cell apoptosis [94]. CSR is a genetic 
rearrangement of switch regions of constant segments in heavy chains to change antibody 
isotypes and improve effector function of antibodies. This recombination is achieved by 
creating double-strand breaks in two different S regions and joining DNA ends together. The 
first antibody isotype ( IgM) can be switched to different isotypes (IgA, IgG, IgD and IgE) through 
this exchange of constant segments [32] (Figure 9).  
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Figure 9 Molecular mechanism of antibody maturation. Different rearrangements of V, D, J 
segments located in the upstream of immunoglobulin gene allow B cells generating an 
enormous primary antibody repertoire. After exposure to antigens, AID introduces mutations in 
recombined VDJ region to improve the affinity of antibodies, and this process is called somatic 
hypermutation (SHM). Red sticks within the variable region indicate point mutations. During 
class switch recombination (CSR), the AID-mediated mutations cause DNA double-strand breaks 
in two different switch regions (S) of constant gene segments, and the two switch regions join 
together releasing intervening DNA fragment as a circle.  CSR process is essential for switching 
the antibody from IgM to another isotype. The figure was modified from a figure in the 
reference [95]. 
 
1.3.2 Activation-induced deaminase (AID) 
Antibody maturation requires an enzyme called activation-induced deaminase (AID) [96], 
which is primarily expressed in germinal center B cells [97]. AID is a DNA-cytosine deminase [98], 
directly targeting single-stranded DNA and converting cytosines into uracils to initiate SHM and 
CSR processes [99](Figure 10).  Post V (D) J recombination, AID-mediated deamination in DNA 
introduces point mutations at high frequency in the V (D) J segment during SHM. However, the 
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conversion of C: G pairs into U:G pairs by AID is just the initiative step of SHM. To acquire 
different types of mutations in Ig locus, SHM process also includes the downstream cellular 
pathway of processing uracils in DNA.  
 
Figure 10 Deamination of cytosines into uracils by AID. 
 
AID-mediated deamination is not the only pathway to create uracils in the genome. 
Uracils can also be introduced through spontaneous water-mediated deamination of cytosine 
and misincorporation of dUMP during DNA replication [100]. Cells remove uracils in the 
genome by uracil-DNA glycosylases through BER pathway. Mammalian cells have four different 
types of uracil-DNA glycosylases including uracil-N glycosylase (UNG), single-strand-specific 
monofunctional uracil (SMUG1), methyl-binding domain glycosylase 4 (MBD4) and thymine 
DNA glycosylase(TDG) [101]. UNG plays a major role in removal and repair of genomic uracils, 
and SUMG1 often works as the backup system [102]. The U: G mismatches mediated by AID are 
processed in several different pathways (Figure 11). Through BER, uracil-DNA glycosylases 
excise uracils restoring C: G pairs. If uracils are unrepaired, through simple DNA replication, U: G 
mispairs lead to C/G to T/A transition mutations [90]. That is because replicative DNA 
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polymerases treat U as T and inserts A across from U template [98]. Besides transition 
mutations, transversion mutations are also found in Ig locus. Hence, DNA replication alone 
cannot contribute to all types of hypermutations on Ig genes of activated B cells. And there 
must be other mechanisms leading to SHM. In error-free BER pathway, UNG removes uracils 
generating AP sites, which are further processed by the downstream enzymes APE1, Pol β and 
ligase to maintain genome integrity. Alternatively, if the resulting AP sites are not repaired, DNA 
replicative polymerases cannot copy them. But they could be bypassed by TLS polymerases, 
which could insert any of nucleotides across from AP site template and introduce either 
transition or transversion mutations at C: G pairs during SHM [103]. It was shown that the 
frequency of mutations in Ig genes was significantly reduced in activated B cells from a mouse 
with deficiency of Pol θ [104]. Other TLS polymerases such as Pol η and Rev1 may also be 
involved in SHM of Ig gene [105, 106].  
Sequence analysis of SHM has showed that mutations in Ig genes occur not only at C: G 
pairs, but also at A: T pairs. Through DNA replication and error-prone TLS processes, the 
mutations are only restricted to C: G pairs not A: T pairs. A number of evidence showed that 
mismatch repair pathway is implicated in SHM to introduce mutations at A: T pairs.  Although 
replicative polymerases have the ability of proofreading, some replication errors still escape 
correction. Cells have developed a conserved repair pathway, MMR to remove incorrect base 
pairs [107, 108]. In human cells, MMR pathway starts with the recognition and binding of 
mismatches by a dimer of MSH2 and MSH6, followed by the excision of the incorrect base and 
its surrounding nucleotides by the exonuclease (Exol). The resulting strand gap generated by 
Exo1 is then repaired by TLS polymerase and ligase [108]. Several reports showed that the total 
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frequency of SHM reduced either in MSH2-/- mice or MSH6-/-mice [69, 109, 110]. More 
interestingly, in the MMR defective mice, the frequency of hypermutations at C: G pairs 
increased while the mutations at A: T pairs decreased [111, 112]. These data suggest that MMR 
pathway is involved in SHM to introduce mutations at A: T pairs. 
 
Figure 11 Mechanism of somatic hypermutation initiated by AID. AID converts C to U in VDJ 
region. The U: G mispairs can be processed in four different ways. Uracils are excised by uracil 
DNA glycosylase (UNG), forming AP sites. Through BER, remaining AP sites are further 
processed by AP endonuclease (APE) and other downstream BER proteins to restore C: G pair. 
Alternatively, these AP sites can be bypassed by translesion synthesis (TLS) polymerase, leading 
to transition and transversion mutations at C: G pairs. If uracils are not removed, A is inserted 
across from U during replication, resulting in C to T transition mutation. Also, the U: G mispairs 
can be processed through mismatch repair (MMR), introducing either transition or transversion 
mutations at A: T or C: G pair. The figure was modified from figures the references [95, 113]. 
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During CSR, AID targets the Sµ region and one of the downstream S regions and 
introduces uracils in two switch regions [114, 115]. UNG is recruited to remove these uracils 
generating AP sites in the S regions. The resulting AP sites are processed by APE forming single-
strand breaks [32]. AID can attack both strands of DNA in a close proximity and create DSBs.  
The DSBs in two S regions generated by AID are joined through NHEJ eliminating the 
intervening sequence as a circle [32]. For examples, in a class switch to Ig G, AID deaminates 
cytosines into uracils in Sµ region and Sγ region and induces the formation of DSBs in the two 
switch regions. The DSBs are processed by NHEJ to accomplish CSR. A series of reports suggest 
that MMR also plays a role in the formation of DSBs during CSR.  
1.3.3 Germinal center reaction and B-cell lymphoma 
Germinal centers (GCs) are structures in secondary lymph nodes which are formed after 
the exposure of naïve B cells to antigens [116]. GCs are involved in the maturation of B cells 
that generate antibodies with high affinity to antigens. The histological structure of GCs consists 
of the dark zone and light zone. In the dark zone, B cells are activated after exposure to antigen 
and undergo proliferation and SHM, while in the light zone antigen-selected B cells undergo 
CSR [117, 118]. The GC B cells producing antibodies with low affinity against antigen will be 
eliminated through apoptosis. But the mature B cells with high-affinity antibodies will 
differentiate into plasma B cells that secret antibodies against infection, as well as memory B 
cells for protecting the body against the same antigen in the future. In GCs, AID is upregulated 
to induce mutations and DSBs in Ig genes and promote SHM and CSR processes. GC reaction is 
essential for the immune system, but may also be implicated in the B cell lymphomagenesis 
[119].  
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Gene expression profiles reveal that Burkitt lymphomas are derived from dark zones of 
GCs, while follicular lymphomas and diffuse large B-cell lymphomas( DLBCL) originate from light 
zones [120] (Figure 12). The chromosomal translocations between Ig gene and proto-oncogenes 
are a hallmark of GC-derived B-cell lymphomas [121]. These translocations may lead to 
dysregulation of oncogenes promoting lymphomagenesis. Antibody maturation events 
including V (D) J recombination, SHM and CSR are associated with such translocations [122-125]. 
For example, errors in V (D) J recombination mediate translocations of IgH locus with BCL2 
locus found in follicular lymphoma [88, 126]. During CSR,  DSBs breaks are not only generated 
in Ig switch regions, but also in Myc locus. This aberrant CSR promotes translocations of Ig gene 
with Myc gene resulting in Burkitt lymphoma [127]. Also, translocations can arise from mistakes 
in SHM process that lead to off targeting of non-Ig genes such as BCL-6. Many studies confirm 
that dysregulation of BCL6 is involved in the pathogenesis of DLBCL [128, 129].  
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Figure 12 Cellular origin of GC-derived B-cell lymphomas. After naïve B cells are exposed to an 
antigen, these cells enter the germinal center, where AID-mediated SHM and CSR take place 
and mature B cells with high affinity to the antigen are formed and differentiated into memory 
B cells and plasma B cells. AID-dependent aberrant SHM and CSR may lead to chromosomal 
translocations and lymphomagenesis. Burkitt lymphoma originates from dark zone of GC 
whereas follicular lymphoma and diffuse large B-cell lymphoma (DLBCL) originate from the light 
zone of GC. The figure was adapted from figures in the references [88, 119]. 
 
1.3.4 AID and GC-derived B-cell lymphoma 
Since AID mediates SHM and CSR processes, AID must be associated with chromosomal 
instability and malignant transformation of B cells in GCs.  Much evidence shows that AID plays 
an essential role in B-cell lymphomagenesis. Sequencing data revealed that AID could act on 
genes outside of Ig locus.  AID-mediated deamination is found in many genes associated with B-
cell lymphomagenesis such as Myc, Pax5, Pim1, Ebf1 and BCL6. As a consequence, AID could 
induce mutations or DNA double-strand breaks in off-target genes, promoting chromosomal 
translocations between Ig gene and oncogenes. Ramiro et al. showed that translocations of IgH 
with c-myc were observed in AID-proficient mice but not detected in AID-deficient mice. This 
result suggests that AID expression is necessary for translocations of IgH/c-myc. Furthermore, 
the overexpression of AID promotes the development of B-cell lymphoma and leukemia in a 
bone marrow transplantation mouse model [130]. However, it is not clear how AID targets non-
Ig genes and contributes to B-cell lymphomagenesis.  
AID expression is strictly regulated in normal B lymphocytes. However, aberrant 
expression and off-targeting activity of AID in B cells may induce tumorigenesis. Cytokines 
secreted from immune cells such as IL-4 and TGF-β, increase AID expression in B cells. HIV-
associated Burkitt lymphomas have the high level of AID expression [131].  Also, expression of 
AID elevated by Epstein-Barr virus (EBV) was shown to be associated with the development of 
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Burkitt lymphomas [132]. Many studies demonstrated that there is a strong correlation 
between B-cell cancers and aberrant expression of AID.  A lot of B-NHL arise from germinal 
center showed constitutive expression of AID [89-91].  Recently, Bhagwat group examined AID 
expression in cancer cell lines derived from germinal centers including Burkitt lymphoma, 
follicular lymphoma and diffuse large B-cell lymphoma, as well as cell lines not derived from 
germinal centers including multiple myelomas (MM), T-cell lymphomas and classical Hodgkin’s 
lymphoma (CHL). AID expression level was determined by RT-PCR and AID enzymatic activity 
assay. It was observed that GC-derived B-NHL cell lines express AID at a high level. Furthermore, 
AID was also overexpressed in FL patient tumor samples as well as DLBCL patient tumor 
samples, whereas AID was expressed at a low level in marginal zone lymphoma (MZL) patient 
samples whose origin is the post-germinal center. 
1.3.5 Genomic uracils in B-cell lymphoma  
Recent studies on sequencing of a variety of cancer genomes revealed that the C-T 
transitions are the most common mutations in human tumors. This suggests that deamination 
of cytosines into uracils mediated by enzymes could be a potential cause of tumorgenesis. Since 
AID is one of major enzymes converting cytosines into uracils and its expression is correlated 
with B-cell cancers, AID could be a potential endogenous source of mutagenesis and contribute 
to the mutational signature in B-cell cancers.  Therefore, studies of genomic uracil load would 
help understanding how AID promotes the development of cancers.  Bhagwat and Krokan 
groups successively demonstrated that the constitutive expression of AID leads to accumulation 
of uracils in the genome of B-cell lymphomas, although they quantified the level of genomic 
uracils with different techniques. Compared to normal human B cells and non-lymphoma 
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cancer cell lines, B-NHL cell lines with higher levels of AID expression show higher levels of 
uracils in their genome. Human B-NHL cell line, Ramos-7 overexpressing AID displayed largely 
increased uracils in their genome, while knockdown of AID decreased genomic uracil load. 
Mouse B cell lymphoma CH12F3 cells transfected with AID-EYFP fusion gene showed a much 
higher level of uracils than control cells with EYFP gene following stimulation. These results 
indicate a positive correlation between AID expression and uracil load. 
AID introduces uracils in B-cell genome. WT mouse B cells and human B cells with ex 
vivo stimulation showed an increase in AID expression correlating with a similar increase in 
UNG2 expression. Therefore, no significant accumulation of genomic uracils was observed in 
these cells, due to the perfect balance between the creation of uracils by AID and excision of 
uracils by UNG2. In contrast, in UNG2-/- mice, the genomic uracil load substantially increased 
following stimulation. Other uracil-DNA glycosylases including SMUG1, TDG and MBD4 are less 
responsible for excision of uracils produced by AID. These observations indicate that UNG2 
primarily contributes to the removal of uracils and maintenance of the balance of genomic 
uracils introduced by AID. There is an inverse connection between UNG2 expression and uracil 
level.  
In normal primary B cells, elevated AID expression does not lead to genomic uracil 
accumulation due to simultaneously increased UNG2 repair capacity.  However, mouse B-cell 
lymphoma cell line CH12F3 with stimulation showed uracil accumulation in their genome, 
although the expression and enzymatic activity of AID and UNG2 increased in a similar pattern 
to those in WT splenocytes. Moreover, human B-NHL cell lines expressing the high level of AID 
showed an increase in either UNG2 and SMUG1 gene expression or uracil excision activity of 
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the nuclear extract. However, compared to normal B cells, genomic uracil levels in these cells 
are still much higher, despite of elevated capacity of uracil removal.  When UGI, a UNG enzyme 
inhibitor, was added in the enzymatic reaction of uracil excision, the ability of nuclear extract to 
excise uracil was almost abolished. This suggested that UNG2 was the enzyme responsible for 
removing uracils in these cells. A good balance between uracil generation and removal results 
in low level of uracil accumulation in the genome of normal B cells. However, B-cell lymphoma 
cells seem to lose this balance and lead to accumulation of uracils. This indicates that the 
function of UNG2 is not effective enough to excise uracils in B-cell cancer cells, although there is 
an increase in its expression and uracil elimination activity of the nuclear extract.  A number of 
studies demonstrated that UNG2 has to be recruited by some protein factors when it acts on 
gene locations where AID introduces uracils. It has been suggested that Rev1 protein could play 
such role in the recruitment of UNG2. Additionally, UNG2 action could be affected by chromatin 
structure; thereby chromatin modifiers may also be involved in the recruitment process. 
Downregulation of these factors could be the reason for the ineffectiveness of UNG2 function 
in these B-cell cancers. Furthermore, Burkitt lymphoma cell line, Raji cells expressed AID at the 
high level. But the number of uracils did not significantly change over several passages, 
suggesting that B cell lymphoma cells may keep a new steady-state level of uracils [92].  
1.3.6 AP sites in B cell lymphomas 
In BER pathway, damaged bases are recognized and excised by a specific DNA 
glycosylase, resulting in the generation of AP sites which are processed by AP endonuclease. 
UNG is the major uracil-DNA glycosylase removing genomic uracils which are misincorporated 
into DNA or introduced by enzymes or drugs. Pemetrexed, a folate antimetabolite, works as a 
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chemotherapy drug for the treatment of non small cell lung cancer (NSCLC) by increasing uracil 
misincorporation in DNA and resulting in genomic instability. Uracils arising from pemetrexed 
treatment are removed by UNG enzyme. The UNG proficient cells displayed increasing number 
of AP sites with increased pemetrexed treatment. However, the level of AP sites always stayed 
a low level in the UNG defective cells treated with different concentration of pemetrexed [79]. 
Therefore, AP sites levels in cells treated with pemetrexed depend on UNG expression.  
UNG plays an essential role in the processes of either SHM or CSR, by processing U:G 
mispairs induced by AID. In UNG proficient mice, mutations at C: G pairs of Ig loci include 65% 
transition mutations and other random mutations, while the UNG-deficient mice showed 95%  
mutations at C: G are transitions. The dramatic shift to transition mutations suggested that the 
deficiency of UNG inhibits the formation of AP sites which are further copied by TLS polymerase 
causing random mutation at C: G pairs. Moreover, in the absence of UNG, the spectrum of Ig 
isotypes from serum was altered, and CSR was greatly inhibited [133]. This could be explained 
by the fact that CSR is also via the generation of AP sites by UNG. Therefore, AP sites resulting 
from the excision of uracils by UNG are crucial intermediates for the processes of antibody 
diversifications. The absence of UNG prevents the development of GC-derived B cell 
lymphomas in a murine model, suggesting UNG might play an active role in the 
lymphomagenesis by promoting the formation of deleterious AP sites and DNA strand breaks 
intermediates [134]. This also indicates that the disruption of downstream BER may drive the 
accumulation of UNG-mediated DNA lesions and contribute to the pathogenesis of B-cell 
lymphoma. Therefore, B-cell lymphoma cells with an excess of uracils would be expected to 
contain the high level of AP sites accumulation in their genomes.  
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1.3.7 B-cell lymphoma therapy 
The treatment for B-cell lymphomas includes chemotherapy and radiation or their 
combination, depending on the type and the stage of B-cell lymphomas. DLBCL is the most 
common type of B-NHL, and it is a very aggressive type of cancer. In most cases, DLBCL is 
treated with R-CHOP, which refers as combination chemotherapy of a monoclonal antibody 
(rituximab) and four chemotherapeutic drugs (cyclophosphamide, hydroxydaunorubicin, 
oncovin and prednisone) (Figure 13). Follicular lymphoma is a slow-growing type of lymphoma, 
but it is difficult to cure completely. In the early stage, follicular lymphoma responds very well 
to radiation therapy. In the advanced stage, the most widely used treatment is chemotherapy 
including R-CHOP and R-CVP (rituximab, cyclophosphamide, vincristine and prednisone). Burkitt 
lymphoma usually grows very quickly and can spread to brain and spinal cord. This type of 
lymphoma has to be treated with intensive chemotherapy that combines at least 4 
chemotherapy drugs with rituximab or radiation therapy.  
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Figure 13 Structures of CHOP chemotherapy (cyclophosphamide, hydroxydaunorubicin, 
oncovin and prednisone).  
 
1.4 Scope and significance 
As AP sites are the most prevalent types of lesions in DNA and many DNA-damaging 
agents can directly or indirectly induce the formation of AP sites, it is of great interest to detect 
and quantify AP sites. The measurement of AP sites will be very helpful to evaluate the effect of 
DNA-targeted chemotherapeutic agents and thereby improve therapies. Although a lot of 
different techniques have been used to label, identify and quantify AP sites, these techniques 
suffer from drawbacks such as cumbersome protocols, low sensitivity, high background, use of 
radioisotopes, incompatibility with a clinical setting, use of a large amount of DNA, etc. Thus, 
there is a critical need to develop a more versatile technique for labeling and detecting AP sites 
with high sensitivity. One goal of this project is to develop a novel and sensitive tool for 
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quantification of AP sites in cellular DNA. To achieve this aim, a small synthetic alkoxyamine 
with a terminal alkyne moiety was developed as a new tool for AP sites quantification in this 
work. This alkoxyamine allows reacting with AP sites and linking with biochemical tags through 
click chemistry for detection and quantification. In addition to quantification of AP sites in vitro, 
this chemical is also used to label AP sites in vivo and allows directly detecting AP sites induced 
in situ by DNA-damaging agents.   
Another use of alkoxyamines is in combination chemotherapy. Alkylating agents such as 
TMZ are against cancer cells by methylating DNA bases and DNA backbone. However, cells can 
excise the products of TMZ treatment such as 7-methylguanine and 3-methyladenine using 
DNA glycosylases, repair resulting AP sites and suppress the effects of TMZ. Drug resistance is 
one big obstacle for chemotherapy. The alkoxyamine that has been used in combination 
chemotherapy to overcome the drug resistance is MX. MX potentiates the cytotoxic effects of 
TMZ by reacting with the AP sites formed through the action of DNA glycosylases and blocking 
the cleavage activity of AP endonuclease. The second goal of the project is to develop other 
alkoxyamines as BER inhibitors to enhance anticancer efficacy of chemotherapy. This work may 
provide new drug candidates to overcome resistance to chemotherapeutic agents and enhance 
antitumor efficacy.  
B-NHL cell lines and patient tumors derived from germinal center exhibit constitutive 
expression of AID. Moreover, the high level of AID expression has been demonstrated to 
coordinate with the high level of uracil accumulation in the genome. However, DNA repair is 
also active, and cells attempt to remove uracils by uracil-DNA glycosylase and create AP sites 
intermediates. Therefore, the excess of uracils in these B-cell lymphomas may result in AP sites 
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accumulation if there is an imbalance in the downstream of BER repair enzymes. In 
combination chemotherapy of MX with an alkylating agent, the use of alkylating agents is 
aiming to promote genome instability and to create AP sites that are targeted by MX. The high 
levels of endogenous AP sites in B-cell lymphoma could also be the target of MX or other 
alkoxyamines. Therefore, alkoxyamines alone could be used to block the repair of an excess of 
AP sites in B cell cancers and cause cell death. The last goal of this project is to develop 
alkoxyamines as antitumor drugs for selectively killing B-cell lymphomas. Alkoxyamines could 
be potential drugs for the specific treatment of B-cell cancers.  
1.4.1 Rationale 
The rationale of this project is that its successful completion will provide a new versatile 
tool to label and quantify AP sites in cellular DNA in multi-tier plate format without the use of 
proteins. The novel technique of AP site labeling will be useful to study genomic instability 
caused by endogenous or exogenous agents. In addition, the inhibitory effect of alkoxyamines 
on base excision repair could be the basis of their use in combination with DNA-damaging 
agents for anti-cancer treatment. This work will strengthen the chemotherapeutic efficacy of 
killing cancers. Finally, this project will provide novel antitumor candidates for selectively 
treating B-cell cancers that have the high level of deleterious AP sites in the genome.  
1.5 Specific aims of research 
Aim 1) A novel chemical is developed as a versatile tool for labeling and quantifying AP sites in 
cellular DNA with high sensitivity. 
Both MX and ARP are well-known alkoxyamines that covalently link with AP sites. While 
MX does not allow tagging of AP sites, ARP is bulky, contains biotin as the only tag and requires 
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proteins and enzymes for its use.  To create a more versatile tool for labeling AP sites, I 
designed small alkoxyamines with a terminal alkyne (Figure 14). This class of chemicals can tag 
AP sites through the reaction between the aldehyde residue of AP sites and alkoxyamines. Also, 
the terminal alkyne functional group allows linking a variety of biochemical tags through click 
chemistry for visualization and detection. Classic click chemistry  is a chemistry of copper-
catalyzed azide-alkyne cycloaddition, which is a well-established bioorthogonal reaction that 
creates stable triazoles and has been used to label sugars, proteins, DNA and other 
biomolecules both in vitro and in situ [135-137]. The reactivity of these chemicals with AP sites 
is determined using synthetic DNA oligomers containing a single AP site. Moreover, they can be 
developed into a new method for detection and quantification of AP sites in cellular DNA. 
Additionally, they can be used to label AP sites in vivo and visualize AP sites locus in cells. The 
smallest alkoxyamine with a terminal alkyne, AA3, is first synthesized and used. 
 
Figure 14 Labeling AP sites with small alkoxyamines. (A) The general structure of 
alkoxyamines(AA) with a terminal alkyne. (B) Use of click chemistry to label AA-adducted DNA 
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( can be biotin, a fluorophore or any other molecule). (C) The structure of O-2-
Propynylhydroxylamine hydrochloride, AA3. 
 
Aim 2) Inhibitory effect of AA3 on AP endonuclease is examined, and AA3 is applied in 
combination chemotherapy to increase antitumor efficacy of DNA-damaging agents. 
MX is known as a BER inhibitor. The reaction of MX with AP sites has been 
demonstrated to inhibit the first enzyme in the repair of AP sites, AP endonuclease [12], and 
this is the basis of its proposed use as part of anti-cancer combination chemotherapy. It has 
been shown that coupling alkylating agents such as TMZ with BER inhibitor MX increases the 
efficacy of killing tumor cells. AA3 is expected to block the action of AP endonuclease and 
inhibit the repair of AP sites. To test that, synthetic oligomers containing an AP site are used to 
assess the inhibition of AA3 on APE-1. Based on its effect on the activity of APE-1, it is used to 
treat cancer cell lines in combination with DNA-damaging agents to improve the effectiveness 
of killing tumors.  
Aim 3) Cytotoxicity of AA3 in B-cell lymphoma cells is examined, and the molecular mechanism 
of AA3 action is elucidated.  
If AP sites are chemically modified by alkoxyamines, they will escape repair by BER 
pathway and the alkoxyamine-AP site adducts would block DNA replication in subsequent cell 
cycle eventually causing cell death. If B-cell lymphoma cells contained an excess of AP sites as I 
anticipated, alkoxyamines could also target these AP sites and kill B-cell lymphoma cells without 
the assistance of other DNA damaging agents. The cytotoxicity of AA3, MX and ARP is evaluated 
in B-cell lymphoma cell lines, as well as normal human B cells and non-B cell lines. Also, the 
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molecular mechanism of cytotoxicity of alkoxyamines in B cell lymphoma cells is elucidated. 
Analogs of AA3 are synthesized to improve drug potency.  
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CHAPTER 2:  MARTIAL AND METHODS 
Portions of the text in this chapter were reprinted or adapted from DNA repair journal, Vol 27, 
Wei, S., Shalhout, S., Ahn, Y., Bhagwat, A.S., A versatile new tool to quantify abasic sites in DNA 
and inhibit base excision repair, Pages 9-18, Copyright (2015), with permission from Elsevier.  
2.1 Cell lines and tissue samples 
2.1.1 Human cell lines 
Human cervical cancer cell line (HeLa), breast cancer cell lines (MCF-7 and MDA-MB-453) 
and embryonic kidney cell line (HEK293T) were obtained from ATCC (American Type Culture 
Collection). Human lung cancer cell line (A549) was kindly provided by Dr. Young-Hoon Ahn 
(Wayne State University). Human Burkitt lymphoma cell lines (Raji and Daudi) and diffuse large 
B-cell lymphoma cell line (Toledo) were obtained from ATCC. Human Burkitt lymphoma cell line 
(Ramos 1) was kindly provided by Dr. Alberto Martin (University of Toronto). Primary human 
epidermal keratinocytes (HEKn) was obtained from Thermo Fisher Scientific. All B-cell 
lymphoma cell lines were cultured in RPMI-1640 medium (Sigma-Aldrich) supplemented with 
10% fetal bovine serum (FBS) (HyClone) and 1% penicillin-streptomycin (Fisher Scientific). HeLa, 
A549 and HEK293T were cultured in DMEM medium (HyClone) with 10% FBS and 1% penicillin-
streptomycin. MCF-7 was grown in MEM medium (HyClone) supplemented with 10% FBS and 1% 
penicillin-streptomycin, while MDA-MB-453 (ATCC) were grown in Leibovitz's L-15 medium 
(Thermo Fisher Scientific) supplemented with10% FBS and 1% penicillin-streptomycin. All 
human cells were incubated at 37°C in a humidified incubator with 5% CO2 in T-25 cm2flasks, T-
75 cm2 flasks or 48-well plates (CytoOne, USA scientific). All cell lines are summarized in Table 2.  
2.1.2   Primary human B cells 
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Normal apheresis blood samples collected from healthy Red Cross donors were kindly 
provided by Dr. Martin Bluth (Wayne State University). The purified B cells were isolated with 
Easy SepTM direct human B cell isolation kit (Stem Cell Technologies). Human B cells were 
cultured in RPMI-1640 medium supplemented with 10% FBS and 1% penicillin-streptomycin 
and activated with 1 µg/mL anti-CD 40 antibody (Peprotech) and 50 ng/mL IL-4 (Peprotech).  
Table 2 Summary of human cell lines used in this research project. 
Number Cell lines Type of Cell Lines Source 
1 HeLa Human cervix carcinoma 
American Type Culture Collection 
(ATCC) 
2 MCF-7 Human breast carcinoma 
American Type Culture Collection 
(ATCC) 
3 MDA-MB-453 Human breast carcinoma 
American Type Culture Collection 
(ATCC) 
4 A549 Human Lung cancer 
Dr. Young-Hoon Ahn, Wayne State 
University 
5 HEK293T Human embryonic kidney 
American Type Culture Collection 
(ATCC) 
6 Raji Human Burkitt lymphoma 
American Type Culture Collection 
(ATCC) 
7 Daudi Human Burkitt lymphoma 
American Type Culture Collection 
(ATCC) 
8 Toledo 
Human diffuse large B-cell 
lymphoma 
American Type Culture Collection 
(ATCC) 
9 Ramos 1 Human Burkitt lymphoma University of Toronto 
10 HEKn 
Human epidermal 
keratinocytes 
Thermo Fisher Scientific 
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2.2 AP site labeling reaction 
A 6-carboxyfluorescein-(6-FAM-) labeled oligonucleotide U-17-mer (5’-6-FAM-
ATTATTAUCCATTTATT-3’, Integrated Device Technology) was used for the AP site labeling 
reaction. The oligomer (4 pmol) was incubated with E. coli uracil DNA glycosylase (UDG, 1 unit, 
New England Labs) at 37°C for 30 minutes in reaction buffer containing 20 mM Tris-HCl (pH 8.0), 
1 mM DTT and 1 mM EDTA to create AP site containing DNA. The alkoxyamine [methoxyamine, 
MX (Sigma-Aldrich); aldehyde reactive probe, ARP (Dojindo Laboratories) or AA3] was added 
into the oligomer solution at indicated concentrations and incubated at 37°C for another 30 
minutes. In some experiments, the pH of the solution was adjusted with HCl or NaOH solution 
following removal of uracil and the pH was confirmed using pH paper. Following the reaction of 
alkoxyamine, unlabeled AP sites were reduced by the addition of NaBH4 (Sigma-Aldrich) to 100 
mM and further incubation for 5 minutes. If this step was omitted, I observed significant 
degradation of the DNA (data not shown). The reactions were stopped by adding formamide, 
loading dye and heating to 95°C for 5 minutes. The DNAs were electrophoresed in 20% 
polyacrylamide gels containing 7M urea and scanned using a Typhoon 9210 phosphorimager 
(GE Healthcare). Product bands in images were quantified using ImageJ software.  
In experiments involving competition between alkoxyamines, AP site containing DNA 
was reacted with the first alkoxyamine at 37°C for 30 minutes. This was followed by the 
addition of the second alkoxyamine and incubation for an additional 30 minutes. The reactions 
were stopped, and the products were analyzed as described above. 
2.3 Click reaction 
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Biotin azide (prepared in Ahn lab) or Cyanine5 (Cy5) azide (Lumiprobe) was added to a 
solution of AA3-linked 17-mer to 0.5 mM followed by the addition of a freshly prepared 
solution of CuBr/TBTA (1:10 in DMSO/t-BuOH 3:1, 0.5 mM, Sigma-Aldrich). The mixture was 
shaken at 45°C for 1 hour. The DNAs were electrophoresed and analyzed as described above. 
 
Figure 15 Structures of biochemical tags. (A) The structure of biotin azide. (B) The structure of 
Cy5 azide.  
 
2.4 Genomic DNA isolation  
Cells were harvested by centrifugation and lysed by incubation for 1hr at 37°C in Tris-
EDTA buffer (TE) containing 2 μg/ml of RNase A and 0.5% SDS, followed by incubation with 
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Proteinase K (100 μg /ml, Qiagen) at 56°C for 3 hours. The DNA was isolated by 
phenol/chloroform extraction and ethanol precipitation and dissolved in TE.  
2.5 Creation of AP sites in genomic DNA by heat and acid treatment 
Genomic DNA was digested with HaeIII (New England Biolabs) and endogenous AP sites 
in DNA were reduced by the addition of NaBH4 to 100 mM. The reducing agent was removed by 
gel filtration, and this DNA was incubated in sodium citrate buffer (10 mM sodium citrate, 10 
mM NaH2PO4, 10 mM NaCl, pH 5.0) at 70°C for various lengths of time (0, 15, 30, 45, or 60 
minutes). The DNA was rapidly chilled on ice and filtered using MicroSpin G-25 columns (GE 
Healthcare) and precipitated with ethanol. 
2.6 AP site quantification assay  
2.6.1 AP site quantification assay using ARP  
 ARP or AA3 was added to a solution of genomic DNA to 2 mM and the DNA was 
incubated at 37°C for 30 minutes. In parallel, a 75 base pair duplex DNA with one uracil (5'-
T37UT37-3'/5'-A37GA37-3') was treated with UDG to create AP sites and was also treated with 
ARP or AA3. This served as an AP site standard. All DNAs were purified by phenol/chloroform 
extraction and ethanol precipitation, followed by MicroSpin G-25 column (GE Healthcare).  
The ARP-tagged DNA was heated at 95°C for 5 minutes, prior to transfer to a positively 
charged nylon membrane. The DNA was UV cross-linked to the membrane using a Beckman UV 
Stratalinker 1800. The membrane was then incubated with Starting Block Blocking Buffer 
(Fisher) at room temperature for 1hour, followed by the incubation of streptavidin-conjugated 
horseradish peroxidase (HRP, Thermo Scientific) in blocking buffer at room temperature for 30 
minutes. After washing with Tris-buffered Saline containing Tween-20 (TBS-T) for 15 minutes, 
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the membrane was incubated in SuperSignal West Dura Chemiluminescent Substrate (Thermo 
Scientific) for five minutes. The emitted light was captured by FluorChem Imaging System 
(Alpha Innotech). The resulting images were analyzed using ImageJ software. When Cy5-
Streptavidin was used, the fluorescence was quantified using Typhoon 9210 phosphorimager 
(GE Healthcare) (Figure 16). 
 
Figure 16 Schematic outline of AP sites quantification assay using ARP. Digested DNA is 
treated with ARP, and ARP-labeled DNA is transferred to a positively charged nylon membrane. 
The membrane is incubated with streptavidin-conjugated horseradish peroxidase (STV-HRP), 
followed by incubation with Chemiluminescent Substrate. The emitted light is detected by 
byFluorChem Imaging System. Alternatively, the membrane with DNA is incubated with 
streptavidin-Cy5 and scanned using Typhoon phosphorimager.  
 
2.6.2 AP site quantification assay using AA3 
AA3-tagged DNA was linked with Cy5 azide using the click reaction and purified by 
ethanol precipitation and filtration through a MicroSpin G-25 column (GE Healthcare). The Cy5-
labeled DNA was heated at 95°C for 5 minutes before being transferred to a positively charged 
nylon membrane. The membrane was scanned using a Typhoon 9210 phosphorimager (GE 
Healthcare). The images were analyzed using ImageJ software. Alternately, the fluorescence of 
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AA3-Cy5 tagged samples was directly measured using Synergy H1 Hybrid Reader (BioTEK) and 
the fluorescence intensities were obtained directly from the instrument. 
 
Figure 17 Schematic outline of AP sites quantification using AA3. Digested DNA is treated with 
AA3, followed by incubation with Cy5 azide. Cy5-labeled DNA is spotted onto a positively 
charged nylon membrane, which is scanned using Typhoon phosphorimager. Alternatively, Cy5-
tagged DNA is transferred to a microplate, and the fluorescence of DNA samples is measured 
using Synergy H1 Hybrid Reader. 
 
2.6.3 Quantification of AP sites in vivo labeled by AA3  
Cells were cultured in the growth medium supplemented with AA3 at indicated times. 
Genomic DNA was isolated using the protocol described in section 2.4, followed by restriction 
digestion with HaeIII (New England Biolabs). Digested DNA was labeled with Cy5 azide through 
click reaction, prior to being transferred to a positively charged nylon membrane. The 
membrane was scanned and analyzed as described above.  
To quantify AA3 in vivo binding in dead and viable cells, Daudi cells were treated with 5 
mM AA3 for 5 hours. The dead cells and viable cells were separated using apoptotic cell 
isolation kit (PromoKine) and collected separately. Genomic DNA was extracted from the cells, 
fragmented with HaeIII restriction digestion and labeled with Cy5 azide for quantification as 
described above.  
2.7 AP endonuclease activity assay 
The cleavage activity of AP endonuclease APE-1 (1 unit, New England Biolabs) was 
assayed using a 6-FAM labeled oligomer (4 pmol) containing a single uracil. The uracil was 
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excised using UDG to create an AP site and the AP site was labeled with an alkoxyamine as 
described above. The APE-1 reaction was performed in the reaction buffer (50mM potassium 
acetate, 20mM Tris-acetate, 10mM magnesium acetate, 1 mM DTT, pH 7.9) at 37°C for 1 h. DNA 
products were stabilized by incubation with NaBH4 and analyzed by gel electrophoresis as 
described above. 
2.8 Killing of cancer cells by AA3 
2.8.1 Trypan blue exclusion assay 
Cells were stained with Trypan blue (HyClone) and counted by TC20TM automated cell 
counter (Bio-Rad Laboratories) which provides the total cell count and cell viability.  Cell 
viability was determined using this assay.  
2.8.2 Killing of HeLa cells by combination chemotherapy 
DNA alkylating agents including methyl methanesulfonate (MMS, Sigma-Aldrich) and 
temozolomide (TMZ, Sigma-Aldrich) were used in combination chemotherapy. MMS was 
dissolved in phosphate buffered saline (PBS). TMZ was dissolved in sterile Dimethyl sulfoxide 
(DMSO). MX or AA3 was dissolved in sterile water, and the pH was adjusted to 7 using NaOH 
solution. The solutions of MMS, MX and AA3 were freshly prepared for each cytotoxicity 
experiment, while TMZ stock was stored at -20°C.  HeLa cells were seeded in 48-well tissue 
culture plates at 3x104 to 6x104 cell/mL cell density and grown overnight in DMEM medium 
with 10% FBS and 1% penicillin-streptomycin. Cells were treated with a DNA alkylating agent 
(MMS or TMZ) or as a combination of a DNA alkylating agent with MX or AA3 at indicated 
concentrations. Cell viability was measured after 24-hour treatment. 
2.8.3 Killing of B-cell lymphoma cell lines by alkoxyamines 
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B-cell lymphoma cell lines (Raji, Ramos 1, Daudi and Toledo) were seeded in 48-well 
tissue culture plates at 2x105 to 5x105cells/mL cell density and cultured in RPMI-1640 medium 
with 10% FBS and 1% penicillin-streptomycin. Cells were treated with alkoxyamines 
(MX/AA3/ARP) at indicated concentrations and harvested after 24 hours. Cell viability was 
determined. 
In MX pretreatment experiment, Daudi cells were treated with MX at 10mM for 6 hours, 
followed by the incubation with AA3 at 1mM for overnight. Cells were harvested, and their 
viability was determined.  
2.8.4 Killing of normal human B cells by AA3 
Normal human B cells were cultured in RPMI-1640 medium with10% FBS and 1% 
penicillin-streptomycin and stimulated with 1 µg/mL anti-CD 40 antibody and 50 ng/mL IL-4. 
After three days, cells were seeded in 48-well plates at 2x105 to 5x105 cell/mL cell density, 
treated with AA3 at indicated concentrations and harvested after 24 hours. The viability of cells 
was determined. 
2.8.5 Killing of non-B cells by AA3 
HeLa, MCF-7, MDA-MB-453, A549, HEK293T and HEKn cells were seeded in 48-well 
tissue culture plates at 3x104 to 6x104 cell/mL cell density and grown overnight in DMEM 
medium with 10% FBS and 1% penicillin-streptomycin. Cells were treated with AA3 at indicated 
concentrations and harvested after 24 hours. The viability of cells was determined. 
2.9 Immunofluorescence microscopy and quantification of fluorescence intensity per nuclei 
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Daudi cells were treated with 5mM AA3 for 5h or 50μg/ml Phleomycin (Sigma-Aldrich) 
for 24 hours and harvested by centrifugation.  The cell pellet was resuspended in a hypotonic 
solution 75mM KCl, incubated at 37°C for 15 minutes and spun onto microscope slides using a 
StatSpinCytofuge (Beckman Coulter). After fixation with cold methanol, cells were blocked with 
3% FBS in Tris-buffered saline (TBS) and incubated with 2µg/mL anti-phospho-histone H2A.X 
(Ser139) antibody solution (Millipore). The slides were washed with TBS, followed by the 
incubation with 1µg/mL goat anti-mouse antibody conjugated to Fluorescein isothiocyanate 
(FITC) (Millipore). Then, the slides were mounted with ProLong® Gold AntifadeMountant with 
DAPI (Thermo Fisher Scientific) after washing with TBS and visualized using a fluorescence 
microscope. The fluorescence intensity per nuclei was analyzed and quantified using ImageJ 
software. Untreated cells served as a negative control, while cells treated with phleomycin 
were a positive control. 
2.10 Cell synchronization 
Cells were treated with or without 100µM L-Mimosine from Koa hoale seeds (Sigma-
Aldrich) for 24 hours to arrest cells at G1 phase. Half of Mimosine-treated cells were harvested 
by centrifugation, resuspended in the fresh growth media and cultured for another 4 hours to 
allow cells to reenter S phase.  The remaining Mimosine-treated cells and untreated cells were 
also cultured for another 4 hours. Cells were seeded in a 48-well plate and treated with AA3 at 
5mM for 5 hours. The viability of cells was determined by Trypan blue exclusion assay.  
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To confirm whether cells were arrested at G1 phase, cell cycle was analyzed by flow 
cytometry with Propidium iodide (PI, Sigma-Aldrich). Briefly, suspension cells were transferred 
into a FACS tube and pelleted by centrifugation. Cell pellet was washed with cold Dulbecco's 
Phosphate-Buffered Saline (DPBS, HyClone) and resuspended into 0.5mL cold DPBS. Cold 70% 
ethanol (4mL) was added dropwise into cell suspension solution to fix cells. After incubation at 
4 °C for 1 hour, cells were pelleted by centrifugation, washed with cold DPBS and incubated 
with 0.5mL PI staining solution at 37 °C for 30min. Cell cycle analyses were performed by BD 
LSRFortessaTM cell analyzer (BD Biosciences). The data of flow cytometry was analyzed by 
FlowJo software. 
2.11 RNA isolation and real-time PCR (RT-PCR) 
Total RNA was isolated from cells using TRIzol reagent (Thermo Fisher Scientific). cDNA 
was synthesized with ProtoScript First Strand cDNA synthesis kit (New England Biolabs) and 
amplified by HotStartTaq polymerase (SA Biosciences).  The primers used for RT-PCR were 
described in the previous paper [92]. RT-PCR was carried out using an Applied Biosystems 7500 
fast real-time PCR system. 
2.12 Synthesis of alkoxyamines 
2.12.1 Synthesis of O-2-Propynylhydroxylamine hydrochloride (AA3) 
AA3 was synthesized according to figure 18. Propargyl bromide (11.3 mmol, Sigma–
Aldrich) was added drop wise into a mixture of tert-butyl-N-hydroxycarbonate (3.7 mmol, 
Sigma–Aldrich) and sodium carbonate (7.4 mmol) in N, N-dimethylformamide (DMF). The 
reaction mixture was stirred overnight at 70°C, washed with water and extracted with ethyl 
acetate three times. The combined organic solution was washed with saturated aqueous 
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sodium chloride (50 mL), dried over sodium sulfate and concentrated. The crude residue was 
purified by silica gel column chromatography (hexane: ethyl acetate = 10:1) to give the 
intermediate product tert-butyl N-(2-propynyloxy)-carbamate. HCl solution (4 M in 1, 4-dioxane, 
2 mL, Sigma–Aldrich) was added to a concentrated solution of tert-butyl N-(2-propyn-yloxy)-
carbamate (2.1 mmol) in dichloromethane in an ice bath and stirred for approximately 20 min. 
The white precipitate was filtered and recrystallized with diethyl ether and ethanol to give O-2-
propynylhydroxylamine hydrochloride (AA3, 0.08 g). Its structure was confirmed by 1H NMR 
and 13C NMR.1H NMR (400 MHz, CD3OD) ẟ: 4.748 (s, 2H, CH2), 3.376 (t, 1H, CCH, J = 2.4 Hz); 13C 
NMR (500 MHz, CD3OD), ẟ: 79.8 (CH2), 74.6 (C), 62.3 (CH). 
 
Figure 18 Scheme of synthesis of AA3. 
 
2.12.2 Synthesis of O-propylhydroxylamine hydrochloride (AA4) 
1-Bromopropane (11.3 mmol, Sigma-Aldrich) was added dropwise into a mixture of tert-
butyl-N-hydroxycarbamate (3.7 mmol, Sigma-Aldrich) and sodium carbonate (7.5 mmol) in DMF. 
The reaction mixture was stirred overnight at 90 °C, washed with water and extracted with 
ethyl acetate three times. The combined organic layer was washed with saturated aqueous 
sodium chloride (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The 
crude residue was purified by silica gel column chromatography (hexane: ethyl acetate = 13:1) 
to give the intermediate product tert-butyl N-(propyloxy)-carbamate. HCl (4M in 1, 4-dioxane, 2 
mL, Sigma-Aldrich) was added to a concentrated solution of tert-butyl N-(propyloxy)-carbamate 
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(2.1 mmol) in dichloromethane in an ice bath and stirred for approximately 30 min. The mixture 
was concentrated and the resulting oil product was recrystallized using diethyl ether/ethanol as 
the solvent to give O-propylhydroxylamine hydrochloride (AA4, 0.07g). Its structure was 
confirmed by 1H NMR.  
 
Figure 19 Scheme of synthesis of AA4. 
 
2.12.3 Synthesis of O-(3-butynyl) hydroxylamine hydrochloride (AA5) 
Diisopropyl azodicarboxylate (DIDA, 40% solution in toluene, 0.0011mol, Sigma-Aldrich) 
was added dropwise to a stirred solution of the 3-butyn-1-ol (0.001 mol, Sigma-Aldrich), N-
hydroxyphthalimide (0.001 mol, Sigma Aldrich) and triphenylphosphine (TPP, 0.001 mol, Sigma-
Aldrich) dissolved in anhydrous tetrahydrofuran (THF, 2.5 mL). After stirring 24 hours at 45°C, 
the solvent was removed. Ether was added to the residue to precipitate triphenylphosphine 
oxide and diethyl hydrazinedicarboxylate, which were filtered off. The filtrate was evaporated 
under reduced pressure, and the residue was purified by silica gel column chromatography 
(hexane: ethyl acetate = 8:1) to give the intermediate product N-(but-3-ynyloxy) phthalimide. A 
mixture of the N-(but-3-ynyloxy) phthalimide (0.5 mmol) and hydrazine monohydrate (0.53 
mmol, Sigma-Aldrich) was vigorously shaken at room temperature for 15 min. Diethyl ether (2 
mL) was added, and the mixture was shaken for another 15 min before it was filtered. The 
residue was washed again with 3 x 3 mL portions of ether. HCl (4M in 1, 4-dioxane, 1 mL, Sigma-
Aldrich) was added dropwise to the combined ethereal filtrate to precipitate out the O-(3-
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butynyl) hydroxylamine hydrochloride (AA5, 21.5 mg) which was filtered, washed with ether 
and recrystallized using 2-propanol/ether as the solvent [138]. Its structure was confirmed by 
1H NMR.  
 
Figure 20 Scheme of synthesis of AA5. 
 
2.12.4 Synthesis of O-(2-azidoethyl) hydroxylamine hydrochloride (AA6) 
To a stirred solution of N-hydroxyphthalimide (3.06 mmol, Sigma Aldrich) in DMF (3.75 
mL), triethylamine (6.74 mmol, Sigma Aldrich) and 1-bromo-2-chloroethane (14.42 mmol, 
Sigma-Aldrich) were added, and the mixture was stirred overnight at 55°C. The solid was 
filtered and the precipitate was washed with DMF until it became white. The filtrate was 
diluted with ethyl acetate and the organic layer was extracted with 1M HCl (x2) and brine. The 
organic phase was dried with anhydrous Na2SO4, filtered and evaporated under reduced 
pressure. To remove the excess alkyl bromide the product was further purified using silica gel 
column chromatography (hexane: ethyl acetate = 8:1) and recrystallized with ethyl acetate/ 
diethyl ether to afford 2-(2-chloroethoxy)isoindoline-1, 3-dione (0.55 g) as a white solid. Its 
structure was confirmed by 1H NMR.  
To a stirred solution of 2-(2-chloroethoxy) isoindoline-1, 3-dione (0.55 g, 2.43 mmol) in 
DMF (4 ml), NaN3 (1.41 g, 21.69 mmol) was added and the reaction mixture was stirred for 2 
days at 55 °C. The reaction was diluted with CHCl3 and H2O, and the organic layer was extracted 
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with CHCl3 (x2) and the organic layers were dried over anhydrous Na2SO4, filtered and 
evaporated under reduced pressure. Then it was further purified using silica gel column 
chromatography (hexane: ethyl acetate = 8:1) and recrystallized using ethyl acetate/ hexane to 
afford 2-(2-azidoethoxy) isoindoline-1, 3-dione (0.30 g) as a white solid. Its structure was 
confirmed by 1H NMR.  
A mixture of the 2-(2-azidoethoxy)isoindoline-1,3-dione (1.3 mmol), hydrazine 
monohydrate (7.78 mmol, Sigma Aldrich) and dichloromethane (3 mL) was vigorously shaken at 
room temperature for 15 min. Diethyl ether (6 mL) was added and the mixture was shaken for 
another 15 min before it was filtered. The residue was washed again with 3 x 3 mL portions of 
ether. Ethereal HCl (4M in 1, 4-dioxane, 2 mL, Sigma-Aldrich) was added drop wisely to the 
combined ethereal filtrate to precipitate out the O-(2-azidoethyl) hydroxylamine hydrochloride 
(AA6, 0.28 g) which was filtered, washed with ether and recrystallized using 2-propanol/ether 
as the solvent. Its structure was confirmed by 1H NMR.  
 
Figure 21 Scheme of synthesis of AA6. 
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CHAPTER 3: RESULTS 
Portions of the text and figures in this chapter were reprinted or adapted from DNA repair 
journal, Vol 27, Wei, S., Shalhout, S., Ahn, Y., Bhagwat, A.S., A versatile new tool to quantify 
abasic sites in DNA and inhibit base excision repair, Pages 9-18, Copyright (2015), with 
permission from Elsevier.  
3.1 Reactivity of a versatile chemical AA3 with AP sites in DNA 
 To create a more versatile tool for labeling AP sites, I designed and synthesized a small 
alkoxyamine with an alkyne group, AA3. I combined the abilities of both MX and ARP into AA3, 
which should react with AP sites in, but also allow linking AP sites to biochemical tags like biotin 
or fluorescent tags through click chemistry for quantification (Figure 22). The reactivity of AA3 
toward AP sites in DNA and was examined using a synthetic DNA oligomer containing a single 
AP site. All reaction products were separated by denaturing polyacrylamide gel. 
 
Figure 22 Use of click chemistry to label AA3-AP site DNA ( can be biotin, a fluorophore or 
any other molecule). 
 
3.1.1 Labeling of AP sites using AA3 
To demonstrate that AA3 reacts with AP sites, we showed that it inhibits the ability of 
ARP to label AP sites. AP sites were created by the excision of uracils by uracil-DNA glycosylase 
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in a synthetic oligomer. They were reacted with ARP and the products separated on a 
denaturing gel. The linking of ARP to DNA caused a shift in mobility of oligomer[33](Figure 23A; 
lane 3). This shift was eliminated completely if the AP sites were pretreated with AA3 (Figure 
23A; lane 6). This shows that AA3 forms a stable adduct at AP sites and blocks the reaction of 
ARP. Treatment of the oligomer with AA3 alone did not create an observable shift in oligomer 
mobility (Figure 23A; lane 5) probably because of the small size of AA3 compared to ARP (MW 
71.0 vs. 331.4). However, treating the oligomer with the two chemicals in the reverse order still 
created the mobility shift (Figure 23A; lane 4) suggesting that ARP-DNA adducts are stable and 
cannot be replaced with AA3.  
AA3 is both versatile and more efficient than ARP in labeling AP sites. AP sites reacted 
with AA3 can be labeled with an appropriate azide using click chemistry. Following a reaction 
with AA3, biotin azide was used to routinely convert greater than 70% of the AP sites to 
biotinylated form (Figure 23A, lane 7). Prior treatment of the AP sites with a reducing agent, 
sodium borohydride, eliminated labeling showing that AA3 reacts with only the unreduced form 
of the AP site (Figure 23B). AA3 reacted equally well with AP sites in ssDNA and dsDNA 
converting an overwhelming majority of substrate to a product (Figure 23C). It may be possible 
to increase the reaction yield through further optimization of the click reaction [139]. In 
contrast, ARP converted less than 20% of the substrate to the biotinylated product (Figure 23A, 
lanes 3, Figure 23C, lanes 2 and 6).  
To show that AA3 can be also used to label AP sites with different tags, we replaced 
biotin azide with Cy5 azide in the click chemistry. Using this strategy, 67% of AP sites in the 
oligomer were labeled with the fluorescent label (Figure 23D, lane 4). As a large number of 
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fluorescent dyes and other molecules are commercially available in azide form, it should be 
possible to choose appropriate labels for AP sites based on the intended application.  
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Figure 23 Reactivity of AA3 toward AP sites in DNA. A scheme for each experiment is shown at 
the top of each part of the figure. (A) Inhibition of ARP reaction by AA3. Briefly, a 5’-6-FAM 
labeled DNA was incubated with UDG to create AP sites and reacted with AA3 and ARP in the 
indicated order. For the reaction in lane 7, DNA was incubated with UDG and AA3, followed by 
reaction with biotin azide using click chemistry.  (B) The 17-mer DNA containing a single AP site 
was reacted with either ARP (lane 2) or AA3 followed by click reaction with biotin azide (BA; 
lane 3). This created characteristic gel retardation of the DNA (indicated by arrows). When the 
AP site was treated with sodium borohydride prior to ARP or AA3 reaction these bands 
disappeared (Lanes 5 and 6, respectively). (C) Comparison of reactions of AA3 with AP sites in 
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double-stranded DNA (lane 3 and 4) and single-stranded DNA (lane 7 and 8). Reactions of ARP 
with double- and single- stranded DNA are shown in lanes 2 and 6, respectively. (D) Labeling of 
AP sites with Cy5 using AA3. AP sites were reacted with AA3 followed by click reaction with 
biotin azide (lane 3) or Cy5 azide (lane 4). 
 
3.1.2 AA3 has better reactivity profile than ARP 
We were surprised that ARP labeled <20% AP sites under the standard conditions (Tris 
buffer, pH 8.0). To investigate this, the pH of the reaction buffer was changed after uracil 
excision, but prior to addition of ARP. When the products were quantified by gel 
electrophoresis the gel showed that ARP reacts well with AP sites only at acidic conditions 
(Figure 24A). We consistently found that with 0.2 M oligomer and 5 mM ARP <20% of the 
substrate was converted to product at pH 7 or 8 (Figure 23 and 24A). In contrast, AA3 was much 
more reactive with AP sites over the pH range of 4 to 8, and converted 57% or greater AP sites 
to AP-AA3 adduct (Figure 23 and 24B). Therefore, AA3 is more suitable for in situ labeling of AP 
sites in cells than ARP. 
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Figure 24 pH dependence of reaction of ARP and AA3 with AP-sites. A scheme for each 
experiment is shown at the top of each part of the figure. (A) Reactions of ARP (5 mM) with AP 
sites at pH 4, 5, 6 and 7 (lanes 3 through 6). (B) Reactions of AA3 (5 mM) with AP sites at pH 4, 5, 
6 and 7 (lanes 3 through 6) followed by the addition of biotin azide. 
 
Under physiological conditions, AA3 was more reactive toward AP sites than ARP even 
at much lower concentrations. Increasing the ARP concentration from 5 to 10 mM resulted in 
an increase in product formation from 13% to 20% (Figure 25A), while AA3 converted greater 
than that amount of substrate to product even at 1 mM (Figure 25B). The results from three 
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independent experiments are presented in Figure 25C. They show that AA3 was much more 
reactive at pH 7 toward AP sites than ARP over a range of concentrations and AA3 was about as 
reactive toward AP sites at 1 mM as ARP was at 10 mM (Figure 25C). 
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Figure 25 Concentration dependence of reactivity of ARP and AA3 with AP sites at pH 7. (A) 
DNA was incubated with UDG to create AP sites and reacted with 2, 1, 5, or 10 mM ARP (lanes 2 
through 5). (B) DNA was incubated with UDG to create AP sites and reacted with 1, 2, 5, or 10 
mM AA3 (lanes 2 through 5) followed by click reaction with biotin azide. (C) Quantification of 
the reaction products of different concentrations of ARP and AA3 with AP sites at pH 7. Mean 
and standard deviation of triplicate samples is shown. 
 
3.2 A technique for quantification of AP sites by AA3 
As ARP has been used to quantify AP sites in genomic DNA of normal cells [27, 28, 140] 
and cancer cell lines [27, 141], we wished to compare the use of AA3 in a similar setting. When 
ARP was used, the DNA adducts were quantified using streptavidin-conjugated horseradish 
peroxidase [27], and when AA3 was used the adducts were tagged with Cy5 for quantification. 
In both cases, the samples were spotted on a nylon membrane using a dot-blot apparatus and 
the light or fluorescence from each dot was quantified. The comparison was done in three 
different ways. 
3.2.1 AA3 can be used to quantify genomic aldehydic lesions and AP sites 
First, genomic DNA was extracted from HeLa cells and the AP sites were quantified using 
ARP or AA3. It should be noted that ARP and AA3 would react with all aldehydic lesions in DNA 
including intact unoxidized AP sites, AP sites cleaved by AP endonuclease, oxidized AP sites and 
formamidopyrimidines which result from alkylation or oxidation of purines in DNA [27, 142]. 
Such lesions occur routinely in cellular DNA, and hence the sites labeled by ARP or AA3 in HeLa 
DNA are referred simply as aldehydic lesions in DNA.  
The results of these experiments are shown in Figure 26. The ARP-based method gave 
about twice as many aldehydic lesions in HeLa as AA3 (Figure 26A). A previous study of HeLa 
DNA using ARP reported [141] somewhat higher number of aldehydic sites (~20 per 106bp). The 
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differences in those numbers and the numbers obtained in our study may be due to methods of 
DNA preparation, age of DNA used and use of different AP site standards. The Mendez et al 
study used depurinated pBR322 as the standard[141], while we used a synthetic oligomer 
containing uracil that was treated with UDG as the AP site standard (Figure 26C). 
In a second set of experiments, HeLa DNA was first treated with sodium borohydride to 
reduce preexisting aldehydic lesions and make them resistant to ARP or AA3. The DNA was then 
heated under acidic conditions to create new AP sites through depurination. The depurination 
reaction was terminated at various times and the AP sites were quantified using the two 
chemicals as described above. The data showed there was a linear time-dependent increase in 
the number of AP sites and the two methods gave comparable numbers for AP sites at all time 
points (Figure 26B, left panel). 
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Figure 26 Quantification of aldehydic lesions and AP sites using ARP and AA3. (A) HeLa DNA 
was labeled with ARP and vacuum-spotted onto a nylon membrane. Aldehydic lesions in this 
DNA were quantified using streptavidin-conjugated horseradish peroxidase (HRP) and detected 
using a chemiluminescent substrate (open bar). In parallel, aldehydic lesions in HeLa DNA were 
also labeled with AA3 and quantified by reaction with Cy5 azide followed by applying DNA to a 
nylon membrane (black bar). AA3-labeled aldehydic lesions reacted with Cy5 azide were also 
quantified in solution using a microplate reader (gray bars). Mean and standard deviation of 
triplicate samples is shown. (B) HeLa DNA was pre-treated with NaBH4 to reduce endogenous 
aldehydic lesions and AP sites were generated by heat and acid treatment for different lengths 
of time. The AP sites were labeled using ARP or AA3 for labeling, and the DNA was spotted onto 
a nylon membrane and the membranes scanned to quantify AP sites (Left). AP sites in the same 
DNAs were also quantified by reacting them successively with AA3 and Cy5 azide, and 
measuring fluorescence intensity directly using a microplate reader (right). Mean and standard 
deviation of triplicate samples is shown for each time point. (C) A 75-mer DNA containing a 
single uracil was treated with UDG to create AP site. Different dilutions of this DNA were 
treated with ARP or AA3 as indicated. This was followed by treatment with HRP-streptavidin 
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followed by incubation with chemiluminescent substrate and the light intensity was quantified 
(left panel), or reacted with Cy5 azide and fluorescence intensity quantified (center and right 
panel). When AA3 was used, the reaction samples were either spotted on a nylon membrane 
(center panel) or measured directly using a microplate reader (right panel). 
 
3.2.2 Sensitivity and ease of use of AA3 
To determine whether AA3-based quantification of AP sites was as sensitive as ARP-
based quantification, we treated different amounts of a DNA oligomer containing AP sites with 
ARP or AA3 and quantified the products. The membrane images from the two parallel 
experiments are shown in Figure 27A. The sample containing 108 AP sites was visible using ARP-
chemiluminescence assay, but the sample with 107 sites could not be detected above 
background. In contrast, 107 AP site sample could be detected in the image from AA3-
fluorescence assay. Adjusting the image brightness did not change the relative sensitivities of 
AA3 and ARP. The membrane containing ARP-labeled samples have much higher background 
than the membrane with AA3-labeled samples (Figure 27B). Thus under these conditions, AA3-
based detection of AP sites has a lower background and greater sensitivity than ARP. 
However, the readout for the comparison of two techniques used to quantify AP sites in 
Figure 27A was different, and I wanted to eliminate this variable in the comparison. To 
accomplish this, I labeled different amounts of the AP site-containing DNA duplex with ARP and 
then bound it to Cy5-streptavidin. In parallel reactions the DNA was reacted with AA3 followed 
by reaction with Cy5 azide. Both sets of samples were spotted on nylon membranes and Cy5 
fluorescence was quantified. The results show that both methods result in a linear relationship 
between the number of AP sites and Cy5 fluorescence (Figure 27C), but the use of AA3 results 
in lower background and hence greater signal-to-noise ratio (Figure 27C, inset). 
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One problem of using ARP to quantify AP sites is the difficulty of separating unbound 
protein (HRP or streptavidin) from that is bound to DNA. In contrast, the AA3-based method 
does not use a protein and hence it is possible to eliminate unreacted AA3 from the much 
larger AA3-DNA by a G-25 mini-column. The Cy5 fluorescence can then be directly measured 
using a microplate fluorometer (Figure 27D). I performed this simplified procedure on 
endogenous aldehydic lesions in HeLa DNA and on AP sites created by heat and acid treatment, 
and the results were comparable to those obtained by the other two methods (Figure 26A, and 
26B, right panel). Thus the use of AA3 simplifies AP site quantification (Figure 27D). 
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Figure 27 Sensitivity of detection of AP sites using ARP and AA3. (A) Image of the nylon 
membranes where different amounts of DNA containing a synthetic oligomer with one AP site 
were labeled using either ARP-HRP (top) or AA3-Cy5 (bottom). (B) The brightness levels in 
images shown in Figure 27A were adjusted using Adobe Photoshop to show more signal. With 
this adjustment, 108 AP sites can be detected using the ARP/HRP protocol, while 107 sites can 
be detected using the AA3/Cy5 azide protocol. (C) Synthetic duplex containing one AP site was 
labeled with either ARP or AA3. Different dilutions of ARP-labeled DNA was spotted on a 
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membrane and bound with Cy5-streptavidin. AA3-labeled DNA was reacted with Cy5 azide, and 
different dilutions were spotted on a membrane. Cy5 fluorescence was quantified in each case 
and is plotted against the number of AP sites in each spot.   
 
3.3 AA3 inhibits APE-1 
The reaction of MX with AP sites is known to inhibit its repair by AP endonuclease [74] 
and this is the basis of its proposed use as part of anti-cancer combination chemotherapy [65]. 
To find out whether ARP and AA3 similarly inhibit AP endonuclease APE-1, I treated an oligomer 
containing an AP site with MX, ARP or AA3 and then challenged the DNA with APE-1. The results 
showed that while MX and AA3 were very effective in blocking the action of APE-1, ARP was a 
poor inhibitor of the enzyme. 
When AP sites were reacted with ARP at pH 7 and the DNA was then treated with APE-1, 
about 90% of the DNA was cleaved by the enzyme showing poor protection of AP sites by ARP 
(Figure 28A, lane 8). This is probably because of the poor reactivity of ARP at pH 7 (Figure 24A). 
In contrast, both MX and AA3 protected an overwhelming majority of AP sites at pH 7 (Figure 
28A, respectively lanes 4 and 6). When the pH of ARP reaction was lowered to 5, protection of 
AP sites against cleavage by APE-1 increased to 26% (Figure 28B, lane 8).Under the same 
conditions, the protection by MX and AA3 was ~100% (Figure 28B, lanes 4 and 6). Thus, MX and 
AA3 protect AP sites against APE-1 cleavage equally well at both pH conditions. 
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Figure 28 Inhibition of APE-1 activity by MX, ARP or AA3. A scheme for each experiment is 
shown at the top of each part of the figure. (A) DNA containing an AP site was reacted with MX, 
AA3 or ARP at pH 7. This was followed by incubation of DNA with APE-1. (B) DNA containing an 
AP site was reacted with MX, AA3 or ARP at pH 5. This was followed by incubation of DNA with 
APE-1. 
73 
 
 
3.4 AA3 kills cells containing DNA base damage 
Inhibition of base-excision repair has been proposed as a strategy for anti-cancer 
chemotherapy [143, 144]. In particular, it has been shown that coupling treatment of cancers 
with alkylating agents such as MMS or TMZ with BER inhibitor MX increases killing of tumor 
cells [43, 65]. To determine whether AA3 is also able to enhance killing cells treated with an 
alkylating agent, I combined AA3 treatment of HeLa cells with MMS or TMZ treatment. 
3.4.1 AA3 enhances cell killing by MMS 
When HeLa cells were treated with a low concentration of MMS (0.5 mM), very little 
loss of viability was observed after one day (Figure 29A). Also, treatment of HeLa cells with AA3 
alone did not kill HeLa cells (data not shown). However, when HeLa cells were treated with 0.5 
mM MMS and different concentrations of AA3, cell viability decreased with increasing 
concentration of AA3 dropping to about 50% survival at 10 mM AA3 (Figure 29A). We then 
directly compared the ability of MX and AA3 to enhance killing by MMS at this concentration 
using six independent cultures for each chemical. The results showed that while MX did 
enhance killing by MMS, AA3 had a stronger lethal effect (Figure 29B).  
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Figure 29 Killing of HeLa cells by combining MMS with MX or AA3. (A) HeLa cells were treated 
with 50 µM MMS and different concentrations of AA3 and cell killing was determined by Trypan 
blue exclusion assay. Each circle represents the result from one independent culture and the 
broken line connects median values at each AA3 concentration. (B) HeLa cells were treated with 
only MMS (50 µM) or with MMS and MX (10 mM) or AA3 (10 mM), and cell killing was 
quantified. The results are from six independent cultures, and the mean and standard deviation 
are shown in each case. 
 
3.4.2 AA3 enhances cell killing by temozolomide 
HeLa cells were treated with 700µM TMZ for 24 hours, and cell viability did not 
significantly decrease. Also, 10 mM MX or AA3 alone did not kill HeLa cells after one-day 
treatment. When cells were treated with 700 µM TMZ and 10 mM AA3, cell viability dropped to 
20% (Figure 30). The result shows that AA3 potentiated the cytotoxic effect of TMZ. Surprisingly, 
the combination of TMZ and MX treatment did not significantly kill HeLa cells. Higher 
concentration of MX may be required to kill cells treated with 700µM TMZ. The results suggest 
that AA3 could more effectively enhance cell killing by TMZ. 
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In both cases, the difference between the killing enhancement caused by MX and AA3 is 
statistically significant and suggests that AA3 is better than MX as a component in anti-cancer 
combination chemotherapy regimen. It is unclear why AA3 kills MMS-treated cells better than 
MX, despite the fact that both chemicals appear to be equally effective at inhibiting APE-1.  
 
 
Figure 30 Killing of HeLa cells by combining TMZ with MX or AA3. HeLa cells were treated with 
only TMZ (700 µM) or with TMZ and MX (10 mM) or AA3 (10 mM), and cell killing was 
quantified Trypan blue exclusion assay. The mean and standard deviation are shown in each 
case. 
 
3.5 AA3 kills B-cell lymphoma cells 
3.5.1 High levels of AP Sites in B-cell cancers 
AP sites in genomic DNA from a number of different human cancer cell lines and two 
types of normal primary human cells were quantified using a previously described procedure 
[145], and the results were normalized to the number of AP sites in the HeLa genome. The 
three GC-derived B-NHL cell lines (Toledo, Raji and Daudi) express AID at high levels [92] and 
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have about 10- to 35-fold higher levels of AP sites in their genomes compared to HeLa (Figure 
31A). In contrast, all the non-B cell lines (A549, HEK293, MDA-MB-453 and MCF-7) had low AID 
expression (Figure 31B) and low levels of AP sites compared to the B-NHL lines (Figure 31A). 
It was previously shown that, in contrast to B-NHL cancers, normal B cells from murine 
spleen or human tonsils do not accumulate uracils in their genomes [92]. This suggested that 
normal B cells may contain fewer AP sites than the B-NHLs. Quantification of AP sites in the 
genomes of B cells from normal human volunteers showed that they had slightly higher levels 
of AP sites than HeLa cells, but lower than the three B-NHL cell lines (Figure 31A). Additionally, 
AP sites in primary neonatal human keratinocytes (HEKn) cells were determined, and these 
were comparable to non-B cell lines. A comparison of AP site levels in the B-NHL lines with non-
B cells or normal human B cells showed that differences between these groups of cells were 
statistically quite significant (Figure 31A). These results confirm the prediction that cell lines 
derived from cancers that express AID at high levels should accumulate more AP sites than 
normal B cells and non-B cell lines. 
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Figure 31 Quantification of levels of AP sites in B-NHL cell lines and non B-NHL cells. (A) 
Comparison of levels of AP sites of three B-NHL cell lines (Toledo, Raji and Daudi) with non B-
cell lines (HeLa, A549, HEK293T, MDA-MB-453, MCF-7 and HEKn) and human B cell. The level of 
AP sites of each cell line is shown relative to that of HeLa cell (set at 1).The average level of AP 
sites of three B-NHL cells is significantly higher than that of five non B-cell lines (****p<0.0001), 
and it is also significantly higher than two normal human cells (B cell and HEKn) (***P<0.0005). 
(B) AID expression levels in B-NHL and non-B cell lines. The levels of AID expression are shown 
relative to gene expression levels of TBP. The asterisk (*) indicates undetectable AID expression. 
 
3.5.2 B-cell lymphoma cell lines are sensitive to AA3 
As alkoxyamines are expected to react with AP sites [28], I wondered whether AA3 
would react with excess AP sites found in B cell cancer lines causing cell death. To test this, four 
GC-derived B-NHL cell lines were treated with AA3 at different concentrations for 24 hours and 
the cell viability was determined using the trypan blue exclusion assay. The results are shown in 
Figure 32. All four cell lines were sensitive to sub-millimolar concentrations of AA3 and at 1 mM, 
AA3 reduced cell viability by about 50% to 80% (Figure 32A). Greater killing was observed in the 
78 
 
 
millimolar range of concentrations and at 10 mM the viability of all the cell lines was reduced to 
below 30% (Figure 32B). Daudi, a Burkitt lymphoma-derived cell line, was consistently most 
sensitive to AA3. Its viability was typically reduced to about 10% at 2 mM AA3 (Figure 32B) and 
hence it was used as a positive control in subsequent experiments. 
 
Figure 32 Killing of B-NHL cell lines by AA3. (A) Killing B-NHL cells by AA3 at sub-millimolar 
concentration. Daudi, Ramos1, Raji and Toledo (2x105 cells/mL seeding density) were treated 
with 0, 250, 500, 1000 µM AA3 for 24 hours and cell viability was determined by Trypan blue 
exclusion assay. (B) Killing B-NHL cells by AA3 at millimolar concentration. Daudi, Ramos1, Raji 
and Toledo (5x105 cells/mL seeding density) were treated with 0, 2, 5, 7.5, 10mM AA3 for 24 
hours. Viability data was normalized to cell viability of untreated cells (set to 100). The mean 
and standard deviation are shown in each case. 
 
3.5.3 Lack of sensitivity of normal cells and non-B cancer lines to AA3 
To determine whether normal B cells were sensitive to AA3, human B lymphocytes were 
isolated from the blood of normal volunteers and stimulated to divide for three days using IL-4 
and anti-CD40 antibody [146]. These cells and the HEKn cells were treated with 5 or 10 mM AA3 
for 24 hours, and cell viability was determined. While neither type of normal cells was 
significantly killed by AA3, Daudi cells treated in parallel cultures were highly sensitive to the 
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chemical (Figure 33A). This shows that AA3 is much more toxic to Daudi cells than normal 
human B lymphocytes or primary keratinocytes and this correlates well with the presence of a 
much higher number of AP sites in Daudi cells (Figure 31A). 
Next, I tested the five non B-NHL cell lines for sensitivity to AA3 and found that none 
was very sensitive to the chemical (Figure 33B). At the highest concentration of AA3 tested, 20 
mM, there was slight sensitivity to the drug, but the reduction in viability was only 10-15% 
(Figure 33B). These results suggest that the low levels of AP sites found in these cell lines make 
them insensitive to AA3. 
 
Figure 33 Cytotoxicity of AA3 in non B-NHL cells. (A) Cytotoxicity of AA3 in normal human B 
cells and primary keratinocytes (HEKn). Normal human B cells isolated from blood of healthy 
donors, HEKn and Daudi were treated with AA3 at 5 or 10 mM and cell killing was determined 
after one day. (B) Cytotoxicity of AA3 in non B-NHL cell lines. Non B-cell cancer cell lines (HeLa, 
MCF-7, MDA-MB 453 and A549) and human embryonic kidney cell line (HEK293T) were treated 
with AA3 at 1, 2, 5, 10, 20mM AA3 for 24 hours and cell viability was determined. Viability data 
was normalized to cell viability of untreated cells (set to 100). The mean and standard deviation 
are shown in each case. 
 
3.5.4 AA3 reacts with AP sites in genomic DNA in vivo 
AA3 has alkyne functionality that can be used to link it with a fluorescent label through 
click chemistry [145]. I used this property to determine whether genomic DNA in Daudi cells 
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treated with AA3 has the chemical linked to the DNA. HeLa or Daudi cells were treated with 
AA3 for 5 or 24 hours, and DNA was extracted from the cells. This DNA was reacted with Cy5 
azide and Cy5 fluorescence was quantified (Figure 34A). There was a small, but significant, 
increase in fluorescence linked to HeLa DNA following 5-hour treatment, but little additional 
increase was seen when the AA3 treatment was extended to 24 hours (Figure 34A). Compared 
to HeLa DNA, the increase in fluorescence intensity linked to Daudi DNA was much greater 
following both 5 and 24 hours of AA3 treatment (Figure 34A). In a different experiment, I used 
the chemical ARP, which also labels AP sites [147, 148]. Daudi cells were treated with AA3 and 
cellular DNA was extracted and labeled using ARP. When the amount of AP sites labeling by ARP 
was quantified using Cy5-Streptavidin, DNA from AA3-treated cells showed much lower levels 
of fluorescence than untreated cells (Figure 34B). These results are consistent with the higher 
levels of AP sites in extracted Daudi DNA compared to HeLa DNA (Figure 31A) and suggest that 
AA3 reacts with AP sites in DNA in vivo. 
As AA3 kills Daudi cells, I wished to determine whether there was a difference in the 
amount of AA3 bound to DNA of cells killed by AA3 compared to the living cells. Following a 5- 
hour treatment of Daudi cells with 5mM AA3 (50% killing), the dead cells were separated from 
the viable cells using an apoptotic cell isolation kit. DNA was isolated from both the cell 
populations and reacted with Cy5 azide, and the fluorescence was quantified. As expected, Cy5 
azide readily reacted with DNA from dead cells showing the presence of covalently linked AA3 
in its DNA (Figure 34C). Surprisingly, DNA from non-apoptotic Daudi cells showed the same 
fluorescence intensity as the untreated cells (Figure 34C). This result suggests that the cells that 
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are not killed by AA3 either prevent the chemical from reaching their genome or are able to 
repair AA3-DNA adducts. 
 
Figure 34 AA3 binds to AP sites in genomic DNA in vivo. (A) Quantification of AP sites of DNA in 
vivo bound to AA3. HeLa and Daudi cells were treated with AA3 for 5 and 24 hours. DNA was 
extracted and labeled with Cy5 azide. The fluorescence intensity of Cy5 represents the level of 
AA3 in vivo binding to DNA (B) Quantification of AP sites in genomic DNA labeled by ARP in vitro. 
Daudi cells were treated with AA3 for 24 hours, and DNA was extracted from cells. Genomic 
DNA was then labeled by ARP, followed by incubation with Streptavidin-conjugated Cy5. The 
intensity of Cy5 fluorescence represents the level of AP sites labeled by ARP after cells were 
treated with AA3. (C) Comparison of the amount of AA3 in vivo binding to DNA in cells killed by 
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AA3 and living cells. Daudi cells were treated with AA3 for 5 hours and dead cells were isolated 
from living cells. DNA was extracted from dead and living cells separately and labeled with Cy5 
azide. The intensity of Cy5 fluorescence indicates the amount of AA3 binding to DNA 
(**P<0.005, n.s. = no significance).  
 
3.5.5 AA3 causes strand breaks in DNA 
It is likely that AA3-AP site adducts in B-NHL cell DNA would block DNA replication 
causing the collapse of the replication fork and resulting in cell death. Thus AA3 treatment 
should cause strand breaks in B-NHL cellular DNA. To test this, Daudi cells were treated with 
AA3 and then stained with anti--H2AX antibodies. Phleomycin-treated Daudi cells served as a 
positive control in these experiments (Figure 35A, bottom panel). While some untreated Daudi 
cells showed a few nuclear -H2AX foci, other nuclei showed no foci (Figure 35A, top panel). 
AA3 treatment caused a large increase in -H2AX foci in the nuclei of most cells (Figure 35A, 
center panel). Fluorescence intensity of -H2AX per nuclei was quantified using ImagJ software 
(Figure 35B). More than 85% untreated cells did not show fluorescence of -H2AX. In contrast, a 
moderate and high level of fluorescence intensity of -H2AX was detected in about 70% AA3-
treated cells.  
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Figure 35 γ-H2AX in Daudi nuclei after AA3 treatment. (A) Representative γ-H2AX 
immunofluorescence images of Daudi cells after 5-hour AA3 treatment. Cells were stained with 
anti γ-H2AX and nuclei were stained with DAPI.  DAPI (blue) images are shown on the left. γ-
H2AX (FITC, green) images are shown in the middle. Merged DIAP and γ-H2AX images are 
shown on the right. Untreated cells served as negative controls (top panel) and phleomycin-
treated cells were positive controls (bottom panel). (B) Quantification of γ-H2AX nuclear 
fluorescence intensity. The intensity of γ-H2AX fluorescence per nuclei was quantified using 
ImageJ software. Cells were divided into three groups based on the intensity of γ-H2AX 
fluorescence per nuclei, including the group with higher than 10,000 fluorescence intensity per 
nuclei (black bar), the group with 1-10,000 intensity (gray bar) and the group with undetectable 
fluorescence(0) (white bar). Percentage of cells of each group in untreated cells (N=171), AA3-
treated cells (N=214) and phleomycin-treated cells (N=152) are indicated.  
 
3.5.6 AA3 cytotoxicity is cell cycle-dependent 
It is likely that AA3-AP site adducts in B-NHL cell DNA block DNA replication causing the 
collapse of the replication fork and cell death. Thus B-NHL cells that enter the S phase should be 
more susceptible to killing by AA3 than those that do not replicate. To test this idea, we 
arrested Daudi cells in the G1 phase by treating them with Mimosine. A 24 hour-treatment of 
cells with Mimosine increased the number of cells in the G1 phase from 21% to 72% and 
release of the Mimosine block for four hours increased the number of cells in both S and G2 
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phases (Figure 36A). All three types of cells were treated with AA3 for five hours and cell 
viability was determined. 
Mimosine-treated Daudi cells were not significantly killed by AA3 (Figure 36B) showing 
that cells in G1 phase are insensitive to AA3. In contrast, the cells that were released from the 
Mimosine block regained their sensitivity to AA3 (Figure 36B). These results show that cellular 
DNA replication is required for the ability of AA3 to kill B-NHL cells. In other words, AA3 should 
only kill cells that undergo cell division. And I analyzed the total number of control cells before 
and after AA3 treatment to confirm that AA3 kills cells that are proliferating. The total number 
of cells was determined using Bio-rad TC20 cell counter.  It was shown that greater than 50% of 
an increase in the total cell number of all of four B-cell lymphoma cell lines and normal human 
B-cells after 24 hours (Figure 36C). This observation confirmed that these cells are proliferating 
well. 
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Figure 36 AA3 cytotoxicity is cell cycle dependent. (A) Cell cycle analysis by flow cytometry 
after Mimosine treatment. Daudi cells were incubated with 100µM Mimosine for 24 hours. 
After that, treated cells were divided into two parts and grown in the medium with and without 
100µM Mimosine separately for 4 hours. Cells were collected, and DNA was stained with 
propidium iodide for flow cytometric cell cycle analysis. (B) Killing of G1-arrested Daudi cells by 
AA3. Daudi cells treated with or without Mimosine (Mimosine treated or control) and cells 
released from Mimosine block (Mimosine removed) were incubated with AA3 for 5 hours and 
cell viability was examined. Viability data was normalized to cell viability of cells without AA3 
treatment (set to 100).The mean and standard deviation are shown in each case (**P<0.005, 
n.s. =no significance). (C) Analysis of the total cell number of B-NHL cells and normal B cells 
before and after 24-hour growth. The total cell number was counted using TC cell counter.  
 
3.5.7 Other alkoxyamines do not kill B-NHL cells 
Methoxyamine reacts with AP sites and has been used to increase the effectiveness of 
known chemotherapeutic agents [143, 149]. However, unlike AA3, MX has not been shown to 
kill any cancer cell on its own. ARP is also known to react with AP sites as AA3 but has also not 
been shown to kill cancer cells. We tested the possibility that MX and ARP may kill B-NHL cells. 
Neither MX nor ARP killed Daudi cells (Figure 37A). At the maximum concentrations tested, 10 
mM, AA3 reduced the viability of Daudi cells to ~10% while MX or ARP showed no significant 
effect on cell viability (Figure 37A). These two chemicals also did not significantly kill other B-
NHL cells, Raji and Toledo (Figure 37A). 
It seemed possible that the lack of sensitivity of Daudi cells and other B-NHLs to MX or 
ARP may be because these chemicals are not efficiently taken up by the cells or are actively 
exported by them. To test this possibility, I pre-treated Daudi cells with MX followed by AA3 
treatment and compared the effects of this sequential treatment on cell viability to treatment 
with AA3 or MX alone. The results showed that MX pre-treatment suppressed the toxicity of 
AA3 (Figure 37B) and strongly suggest that both MX and AA3 react with the same cellular 
targets, presumably AP sites in DNA. 
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Figure 37 Killing of B-NHL cell lines by other alkoxyamines. (A) Cytotoxicity of MX or ARP in B-
NHL cell lines. Daudi, Raji and Toledo were treated with 10mM MX or ARP or AA3 for 24 hours, 
and cell killing was analyzed. (B) Inhibition of AA3 cytotoxicity in Daudi cells by pre-treating MX. 
Daudi cells were treated with 10mM MX for 6 hours, followed by incubation with 2mM AA3. 
Cell viability was determined after 24 hours and normalized to that of untreated cells (set to 
100). The mean and standard deviation are shown in each case (** P<0.005, n.s. = no 
significance). NT stands for untreated cell. 
 
3.5.8 Alkyne functionality of AA3 is important for its toxicity 
The lack of toxicity of MX and ARP for B-NHL cells suggested that the alkoxyamine 
functionality within AA3 was not sufficient for its biological action. As the only other functional 
group within AA3 is the weakly reactive alkyne groups connected to the alkoxyamine by a 
methylene bridge (Figure 38A), variants of this functional group were synthesized and their 
toxicity toward Daudi cells was tested. In particular, I synthesized and tested molecules in which 
the alkyne functionality was replaced with a methyl group (AA4) or an azide group (AA6) and a 
molecule in which the alkyne was separated from the oxygen by an additional carbon-carbon 
bond (AA5; Figure 38A). 
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         Remarkably, neither compounds lacking the alkyne functionality, AA4 and AA6, was toxic 
to Daudi cells (Figure 38B). In contrast, AA5, which contains the alkyne functionality killed these 
cells, but less efficiently than AA3 (Figure 38B). These results suggest that the bioorthogonal 
alkyne functional group is required for the toxicity of these alkoxyamines toward B-NHL cells, 
and their effectiveness is modulated by the distance between alkoxyamine and alkyne groups. 
 
Figure 38 Cytotoxicity of AA3 analogs including AA4, AA5 and AA6. (A) Cytotoxicity of AA3 and 
analogs in Daudi cells. Daudi cells were treated with different alkoxyamines at different 
concentration (0, 1, 2, 5, 10mM) for 24 hours. Cell viability was normalized to that of untreated 
cells (set to 100). The mean and standard deviation are shown in each case. (B) Structures of 
AA3, AA4, AA5 and AA6. 
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CHAPTER 4: DISCUSSIONS AND FUTURE DIRECTIONS 
4.1 AA3 efficiently labels and detects AP sites in DNA 
In this study, I created a small alkoxyamine with alkyne functionality called AA3. The 
reactivity of AA3 toward AP sites was examined using a synthetic oligomer. However, the 
linking of AA3 to AP sites did not create a shift in mobility of DNA band due to the small size of 
AA3. Therefore, I carried out the competition experiment with ARP and the experiment for the 
direct detection of AA3 binding through click reaction. Both of them confirmed that AA3 labels 
AP sites of DNA more efficiently than ARP at physiology condition (Figure 23A, 23B). Compared 
to AA3, ARP is much larger. Hence, the steric hindrance of ARP could inhibit its reactivity toward 
AP sites. In the competition experiment, the ARP-tagged product was hardly visualized after 
DNA substrate was first incubated with AA3 (Figure 23A, lane 6), suggesting all AP sites in DNA 
were bound by AA3. But following the reaction with AA3, biotin azide did not entirely convert 
substrates to biotinylated form. The reason could be that click reaction is not complete. Further 
optimization of click reaction needs to be carried out to improve the efficiency of this reaction.  
AA3 has a better pH profile than ARP. AA3 converted 57% or more DNA to the product 
over the pH range of 4 to 7. In contrast, less than 20% of the substrate was labeled by ARP at 
pH 7 while greater than 70% DNA was tagged by ARP at pH 4 to 5 (Figure 24). This result 
suggests that ARP can react with AP sites more efficiently at the acidic condition. In the 
condensation reaction between aldehyde and alkoxyamine, the nucleophilic nitrogen of an 
alkoxyamine attacks the electrophilic carbonyl carbon of an aldehyde to form as a stable oxime. 
Under the physiological condition, the reactivity of ARP is relatively low because the 
nucleophilic addition of ARP is sterically hindered. However, at the acidic condition, oxygen of 
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the carbonyl group of an aldehyde is protonated. This protonation increases the electrophilicity 
of carbonyl carbon and confers carbonyl group more susceptible to nucleophilic attack by ARP. 
Therefore, acids catalyze this condensation reaction and increase the reactivity of ARP toward 
AP sites in DNA. 
A novel technique for quantification of AP sites in cellular DNA using AA3 was developed 
in the study, and it shows greater sensitivity and lower background than ARP-based ELSA like 
assay. The membrane from the ARP-based assay displayed much higher background than that 
from the AA3-based assay (Figure 27A). In the AA3-based detection method, prior to being 
transferred onto a membrane, processed samples are purified by ethanol precipitation or some 
spin column, which removes unlabeled fluorescent azides eliminating background.  In the ARP-
based method, the membrane has to be incubated with streptavidin-conjugated HRP or 
fluorescence molecule to visualize and detect ARP binding [92, 147, 148]. However, it is hard to 
completely eliminate non-specific binding of streptavidin protein or fluorescent molecule onto 
the membrane through the washing step. This problem may result in a considerable 
background. Furthermore, ARP is less reactive with AP sites in a short oligo (17-mer) (Figure 25). 
It is much possible that the reactivity of ARP could be much lower when it reacts with genomic 
DNA. Hence, in addition to high background, the low reactivity could also contribute to the 
lower sensitivity of ARP-based detection assay.   
As AA3 contains alkyne functionality, in vivo labeling of AP sites by AA3 can be detected 
through click chemistry. To determine whether AA3 binds to AP sites of DNA in vivo, cells were 
treated with AA3 and AA3 binding was then detected by incubation of genomic DNA with Cy5 
azide. In the study, this method was used to examine whether AA3 reacts with AP sites in Daudi 
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cells. However, neither MX nor ARP has this ability. Although ARP contains a biotin tag for 
detection, ARP is bulky and may pass hardly to the cell membrane. Biotin also exists in cells, and 
the use of ARP for labeling AP site in live cells would cause non-specific binding.  Additionally, 
the effectiveness of ARP in labeling AP sites in live cells would be largely affected by its low 
reactivity. MX is a small molecule and can easily enter cells through diffusion, but it does not 
have any tag. Radioisotope technique has to be used for the detection of MX binding in vivo 
[24]. Hence, AA3 is an ideal tool to label AP sites in live or fixed cells and to monitor the 
formation of AP sites in situ by DNA damaging agents.  
4.2 AA3 inhibits base excision repair and is more effective to enhance the cytotoxicity of DNA 
alkylating agents than MX. 
MX is well known as a BER inhibitor, which blocks the cleavage of AP sites by AP 
endonuclease[8]. I have shown that AA3 inhibits APE1 activity as well as MX but ARP is a poor 
inhibitor of APE1 at the physical condition. The failure of inhibition of ARP on APE1 enzyme 
could be attributed by the relatively low reactivity of ARP toward AP sites. Since AA3 and MX 
inhibit APE1 enzyme equally well, it was expected that AA3 should be as good as MX when it is 
used in combination chemotherapy to improve antitumor efficacy of DNA alkylating agents. 
Surprisingly, AA3 is more efficient than MX to kill cancer cells treated with MMS or TMZ. One of 
the reasons could be that cells process AA3-bound DNA and MX-bound DNA differently. It has 
been reported that MX-AP sites in DNA could be removed by long-path BER pathway [77]. 
Other studies show that MX-AP sites could be excised through NER pathway [77]. These 
evidences indicate that it is possible that a part of MX-AP sites could be repaired, although the 
mechanism is not clear yet. The differences between MX and AA3 in chemical structure and size 
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could result in that AA3-AP sites are less susceptible to these repair pathways. Further work 
needs to be done to clarify why AA3 is better than MX in combination therapy.  
When HeLa cells were treated with TMZ and MX, MX failed to significantly increase cell 
killing by TMZ. Many studies have shown that MX is capable to sensitize brain tumor cells to 
TMZ treatment [43, 81, 149]. HeLa cells may be not sensitive to TMZ treatment. As a 
consequence, this concentration of TMZ may not induce enough AP sites. In contrast, AA3 is 
more effective so that binding a moderate level of AP sites by AA3 may cause cell death. 
Therefore, increasing the concentration of either TMZ or MX could improve cell killing. In 
addition to MMS and TMZ, other DNA-damaging agents could also be combined with AA3 to 
increase antitumor efficacy of chemotherapy. For example, AA3 will be used in combination 
therapy with pemetrexed, which has been successfully coupled with MX to kill lung and other 
solid tumors [79, 150].  
4.3 AA3 specifically kills B-cell lymphoma cells 
Blockage of BER pathway by targeting AP sites could be considered as a potential 
strategy for cancer therapy. Two recent papers [90, 92] have shown that B-cell lymphomas 
derived from germinal centers have high levels of genomic uracils induced by AID.  When cells 
endeavor to maintain genomic stability by removing these uracils through the action of uracil-
DNA glycosylase, this will lead to the formation of AP sites. Therefore, these B-cell lymphoma 
cells may have high levels of AP sites accumulation in their genomes, if there is an imbalance of 
the downstream enzymes. To confirm this, I quantified AP sites in B-cell lymphoma cells. Cell 
lines derived from Burkitt lymphoma (Raji and Daudi) and DLBCL (Toledo) showed relatively 
high levels of endogenous AP sites compared to normal human B cells (Figure 31A). In this study, 
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AP sites were quantified by the AA3-based assay which is based on the reaction between AA3 
and the aldehyde residue of an AP site. Therefore, AP sites detected by AA3 in this assay could 
be aldehydic lesions in DNA including intact AP sites, cleaved AP sites and other sites with the 
aldehyde moiety [151]. Moreover, AP sites are often created in several different ways. Thus, AP 
sites in B-cell lymphoma cells reported here are not entirely generated through the excision of 
uracils by uracil-DNA glycosylases. But up-regulated UNG2 expression upon the induction of 
uracils observed in these cells [92] could be one major cause for the increase in AP sites.  
Additionally, I also analyzed AP sites in non-B cells that express AID at very low levels (Figure 
31B). All of them show much lower levels of AP sites than B cell cancers (Figure 31A). These 
results indicate that AID expression may be associated with the formation of AP sites and 
incomplete downstream repair results in accumulation of AP sites. 
As B-cell lymphoma cells have high levels of AP sites in their genome, I hypothesized 
that AA3 could be used to target these AP sites and kill cells. In this study, I demonstrated AA3 
alone can effectively kill B-cell lymphoma cells at a sub-millimolar concentration (Figure 32A), 
but it is not toxic to normal human cells including B lymphocytes and keratocytes even at high 
concentration (10mM) (Figure 33A). Although chemotherapy has been the most prevalent 
strategy for anticancer treatment for decades, one major limitation in the use of current 
chemotherapeutic agents arises from toxicity to normal cells. Reducing side effects to patients 
is still one of the main issues that need to be addressed during drug discovery and development. 
As AA3 is not toxic to normal cells, AA3 could be a potential candidate for antitumor treatment. 
An additional finding is that AA3 at high concentration (10mM) did not significantly kill other 
types of cancer cells such as HeLa, MCF-7, A549 and MDA-MB 453 (Figure 33B), suggesting that 
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AA3 selectively kills B-cell cancers. If AA3 killed cells by targeting AP sites as I proposed, the 
level of AP sites may be the key factor that determines the sensitivity of cells to AA3 treatment. 
AP sites detected in these non-B cells are 12 fold lower relative to B-cell cancer cells in average 
(Figure 31A). This could explain why they are resistant to AA3 treatment. Furthermore, 
compared to the sensitivity of four B-cell lymphoma cell lines tested in the study to AA3, Daudi 
cells appear to be more sensitive than other three cell lines (Figure 32A). This result is 
consistent with the fact that Daudi cells show a higher number of AP sites than others (Figure 
31A).  
The success of AA3 in killing B-cell cancers encouraged me to treat these cells with other 
alkoxyamines. MX and ARP were used to treat Daudi, Raji and Toledo cells. However, no 
significant cell killing by either MX or ARP was observed, except that less than 10% Raji cells 
were killed by MX (Figure 37A). Conversely, AA3 at the same concentration killed most of these 
cells. The reasons for the failure of killing cells by ARP could be that the reactivity of ARP with 
AP sites is much lower than AA3 [151]and ARP may be harder to pass through the cell 
membrane because of its bulky size. As MX is well known to kill cancers treated with DNA-
damaging agents by targeting AP sites and blocking DNA repair [8, 81, 152], I highly anticipated 
that MX could also kill B-cell cancers showing high levels of AP sites. However, the result of cell 
killing by MX is extremely surprising. In this project, I have shown that MX enhances cell killing 
by MMS, but it is not as good as AA3. As I described above, a portion of MX-AP sites may be 
repaired or removed through a certain pathway. This could also result in that MX kills B-cell 
cancers less efficiently than AA3. MX even at a high concentration (10mM) did not kill these 
cells significantly. The resistance of these cells to MX could arise from the complete removal of 
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MX-AP sites by upregulated repair proteins in these B-cell cancers. In contrast, the high level of 
AA3 in vivo binding to Daudi DNA shown in figure 34A suggests that AA3-adducted DNA could 
not be removed and thereby it causes cell death. Secondly, drug uptake and efflux could be 
associated with the failure of killing B-cell cancers by MX. However, MX was shown to inhibit 
cell killing by AA3 when cells were pretreated with MX (Figure 37B), implying that MX targets 
cellular DNA and blocks AA3 binding. The result demonstrated that MX could be efficiently 
taken up by these cells. Therefore, the issue of drug uptake can be ruled out. Further studies 
are needed to understand the drastic difference between MX and AA3 in the toxicity for B-cell 
lymphoma cells, despite the fact that they show similarity in reactivity with AP sites.  
Understanding the molecular mechanism of AA3 cytotoxicity in B-cell cancers will be 
useful for development AA3 as a drug for anti-tumor treatment. I first proved that AA3 
covalently links to AP sites in B-cell lymphoma cells. Daudi cells treated with AA3 showed a 
great reduction in AP sites in genomic DNA detected by ARP-based assay (Figure 34B), indirectly 
suggesting that AA3 binds to AP sites in cells preventing ARP from bindings to genomic DNA in 
vitro.  Similarly, when MX is used in combination therapy with DNA-damaging agents like TMZ 
and pemetrexed, the level of AP sites detected by APR decreased after MX treatment [7, 43, 
150].  
Also, I directly demonstrated that AA3 binds to DNA in vivo, by detecting and 
quantifying AA3-bound sites in DNA through click chemistry. In this experiment, I observed AA3 
in vivo binding in both Daudi and HeLa cells after AA3 treatment, but the level of AA3-bound 
sites in Daudi cells was much higher than that in HeLa (Figure 34A). That is because Daudi cells 
have more AP sites than HeLa (Figure 31A). Also, it was found the level of AA3 binding in Daudi 
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cells greatly elevated with the increasing length of AA3 treatment (Figure 34A).  One reason 
could be that it takes more time for AA3 to completely bind to all AP sites of cells. The longer 
cells are incubated with AA3, the more AA3 binds to DNA.  Moreover, lot of DNA from dead 
cells is often lost during DNA extraction procedure, and cells with high level of AA3 binding are 
more likely to die or be dying. Therefore, the amount of DNA extracted from cells with high 
levels of AA3-bound sites is less than that from cells with low levels of AA3-bound sites. Since 
the percentage of dead cells after 5-hour treatment was lower than that after 24-hour 
treatment, DNA from dead cells with high level of AA3 binding after 5-hour treatment is diluted 
more. This could be the second reason that results that the overall level of AA3-bound sites in 
cells with 5-hour treatment are lower. Thirdly, dead cells are likely to take more AA3, since the 
membrane of dead cells is more permeable. This could also result in that the level of AA3 
binding is higher after 24-hour treatment. Theoretically, AA3 binding should not be observed in 
cells without treatment. However, the control cells showed a small amount of AA3 binding, 
which could result from the background of this assay.  
In another experiment, MX inhibited cytotoxicity of AA3 in Daudi cells that were 
pretreated with MX (Figure 37B), further indicating that MX and AA3 share the same target, AP 
sites. We compared the level of AA3-bound sites in viable cells and dead cells after AA3 
treatment. Dead cells showed an extremely high level of AA3 binding, whereas the level of AA3 
binding in viable cells is as low as that in control cells (Figure 34C). This result strongly indicates 
that AA3 binding to DNA is associated with cell death.  
There is some evidence showing that MX enhances the cytotoxicity of DNA-damaging 
agents via induction of DNA breaks and cell apoptosis [43, 80, 144]. The unprocessed MX-AP 
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adducts block the progression of DNA replication and cause replication fork collapse resulting in 
the accumulation of DNA breaks. I found AA3 inhibited cell growth. This inhibition could result 
from the stalled DNA replication fork caused by AA3-DNA adducts. Moreover, when DNA 
replication was blocked by arresting cells at G1 phase, cells exhibited less sensitivity to AA3 
treatment (Figure 36B). It clearly implies that DNA replication process is necessary for AA3 
cytotoxicity. I also detected a significant increase in DNA double-strand breaks in AA3-treated 
cells by immunostaining γ-H2AX (Figure 35). Altogether, these results indicate the molecular 
mechanism of AA3 action could be that AA3 reacts with AP sites in B-cell cancers and AA3-DNA 
adducts lead to cell death by blocking DNA replication and inducing DNA breaks (Figure 39).  
 
Figure 39 The proposed mechanism of AA3 cytotoxicity in B-cell cancers. AA3 covalently binds 
to B-cell cancer genome, but the AA3-bound AP sites are resistant to DNA repair. As a result, 
AA3-DNA adducts cause cell death by blocking DNA replication fork and elevating DNA breaks. 
 
Although AA3 alone can kill B-cell cancers, the IC50 of AA3 in Daudi cells (500µM) is high. 
Thus, there is a need to improve its potency through combination with other antitumor drugs 
or chemical modification. AA3 will be coupled with DNA-damaging agents or BER inhibitors to 
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increase its antitumor efficacy and reduce IC50. To improve drug efficacy via structure 
modifications, I investigated what functional group is necessary for AA3 toxicity. Since MX and 
AA3 display different toxicity in B-cell lymphoma cells, what structural difference contributes to 
their functional difference needs to be examined.  Three AA3 analogs were synthesized (Figure 
38B). AA4 and AA6 that do not contain the alkyne functionality fail to kill Daudi cells. But AA5 
with a terminal alkyne is toxic to Daudi cells although it is slightly less effective than AA3 (Figure 
38). This data demonstrated the alkyne functional group rather than the bigger size is 
responsible for AA3 cytotoxicity in B-cell lymphoma cells. This finding is very surprising since the 
alkyne group is often considered as an unreactive functional group at physiological conditions. 
Terminal alkynes are widely used in bioorthogonal chemistry for labeling biomolecules due to 
their inert property.  One previous paper reported a reaction between terminal alkynes and 
Cysteine in proteases, in which a terminal alkyne reacts with a thiol of Cysteine forming a vinyl 
thioether linkage [153]. The terminal alkyne group of AA3 may bind to certain proteins such as 
DNA repair machinery proteins through this reaction and prevent AA3-bound AP sites from 
being repaired. Further experiments need to be carried out to elucidate how the alkyne 
functionality contributes to AA3 cytotoxicity in B-cell lymphoma cells.  
In summary, the results of this project demonstrated that a small alkoxyamine, AA3, 
that efficiently label AP sites in cellular DNA can be used in combination therapy coupling with 
DNA-damaging agents and specifically kill these B-cell lymphoma cells with high level of AP sites. 
B-cell lymphomas are typically treated with a combination of a monoclonal antibody (rituximab) 
and at least four chemotherapeutic drugs such as cyclophosphamide, doxorubicin, vincristine 
and prednisone. In this study, AA3 is able to kill these cancer cells without the assistance of 
100 
 
 
other antitumor drugs.  This work suggests the family of alkoxyamines could be proposed as a 
unique class of anti-cancer drugs.   
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Abasic (AP) sites are the most common type of lesions in DNA. Numerous endogenous 
and exogenous agents and cellular processes can induce the formation of AP sites in DNA. If left 
unrepaired, the deleterious AP sites cause mutagenesis and cytotoxicity. Methoxyamine is 
known to react with AP sites and block base excision repair. Another alkoxyamine, aldehyde-
reactive probe (ARP) tags AP sites with a biotin and has been widely used to quantify these sites. 
In this study, I have combined both these abilities into one alkoxyamine, AA3, which reacts 
toward AP sites with better reactivity than ARP at physiological pH. Additionally, AA3 containing 
an alkyne functionality is able to tag AP sites with a biotin and a fluorescent molecule through 
click chemistry. AA3 is used for AP site quantification with greater sensitivity and lower 
background than ARP. AA3 also inhibits the first enzyme in the repair of AP sites, APE-1, to 
about the same extent as methoxyamine. Furthermore, AA3 enhances the ability of alkylating 
agents to kill cancer cells and is more efficient in such combination chemotherapy than 
methoxyamine. 
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The majority of B-cell malignancies originate from germinal centers, where the 
processes of somatic hypermutation (SHM) and class switch recombination (CSR) for antibody 
maturation are initiated by activation-induced deaminase (AID). AID deaminates cytosines in 
DNA creating uracils. It has been previously shown that B-cell lymphoma cell lines and patient 
tumors express AID at high levels and contain high levels of uracils in their genome. These cells 
also contain uracil-DNA glycosylases that remove uracils forming AP sites. I have demonstrated 
that B-cell lymphoma cell lines contain much higher levels of AP site accumulation than normal 
B cells and non-B cell lines. AP sites are able to react with alkoxyamines forming a stable oxime. 
This principle was used to block the repair of an excess of AP sites in B-cell cancers by 
alkoxyamines. AA3 effectively kills B-cell lymphoma cell lines that show high levels of 
endogenous AP sites. In contrast, AA3 is not toxic to normal human B cells, as well as non-B cell 
lines. However, neither MX nor ARP displays cytotoxicity in these B-cell cancers, although both 
of them can target to AP sites. Additionally, AA3 links covalently to B-cell cancer genome, and 
AA3-DNA adducts cause cell death by blocking DNA replication and elevating DNA strand breaks. 
To determine which functionality of AA3 is responsible for its cytotoxicity, I designed and 
synthesized a series of AA3 analogs. Using this approach, I have demonstrated the alkyne 
functional group is required for AA3 toxicity in B-cell cancers. Overall, this new family of 
chemicals could be further developed as novel anti-cancer drugs.   
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